,Drug_1,drug2,Level_of_interaction,Quality_of_interaction,Summary,Description
0,Lapatinib,Acarbose,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose, the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological activity and is metabolised by intestinal enzymes and microbial flora. Lapatinib is unlikely to interfere with this metabolic pathway.",See Summary
1,Lapatinib,Acenocoumarol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Acenocoumarol is mainly metabolised by CYP2C9 and to a lesser extent by CYP1A2 and CYP2C19. Lapatinib does not inhibit or induce CYPs 2C9, 1A2 or 2C19.",See Summary
2,Lapatinib,Acetylsalicylic acid (Aspirin),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Aspirin is rapidly deacetylated to form salicylic acid and then further metabolised by glucuronidation (by several UGTs, major UGT1A6). Lapatinib does not inhibit or induce UGT1A6.",See Summary
3,Lapatinib,Agomelatine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Agomelatine is metabolised predominantly via CYP1A2 (90%), with a small proportion metabolised by CYP2C9 and CYP2C19 (10%). Lapatinib does not inhibit or induce CYPs 1A2, 2C9 or 2C19.",See Summary
4,Lapatinib,Alendronic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Alendronate is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, alendronate should be separated from food or other medicinal products and patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.",See Summary
5,Lapatinib,Alfentanil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alfentanil undergoes extensive CYP3A4 metabolism. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. For administration routes other than oral, a clinically relevant interaction is not expected.",See Summary
6,Lapatinib,Alfuzosin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Alfuzosin is metabolised by CYP3A. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered alfuzosin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45% increase in midazolam AUC. A similar effect may occur with alfuzosin. Care should be taken when orally administered alfuzosin is coadministered with lapatinib. Monitoring for alfuzosin toxicity is recommended.",See Summary
7,Lapatinib,Aliskiren,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Aliskiren is minimally metabolised and is mainly excreted unchanged in faeces. Aliskiren is also a substrate of P-gp. Lapatinib is an inhibitor of P-gp and may increase concentrations of aliskiren. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with aliskiren. If coadministration appears necessary, monitoring of blood pressure is recommended.",See Summary
8,Lapatinib,Allopurinol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Allopurinol is converted to oxipurinol by xanthine oxidase and aldehyde oxidase. Lapatinib not interfere with this metabolic pathway.,See Summary
9,Lapatinib,Alosetron,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. In vitro data indicate that alosetron is metabolised by CYPs 2C9, 3A4 and 1A2. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of alosetron may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with alosetron. Care should be taken when orally administered alosetron is coadministered with lapatinib. Monitoring for alosetron toxicity is recommended.",See Summary
10,Lapatinib,Alprazolam,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Alprazolam is mainly metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered alprazolam may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with alprazolam. Care should be taken when orally administered alprazolam is coadministered with lapatinib. Monitoring for alprazolam toxicity is recommended.",See Summary
11,Lapatinib,Aluminium hydroxide,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Aluminium hydroxide is not metabolised. Lapatinib is unlikely to interfere with this pathway. The solubility of lapatinib is pH-dependent. Pre-treatment with a proton pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 26%. A similar effect may occur with aluminium hydroxide. If coadministration is clinically necessary, lapatinib should be administered at least 2 hours before or 4 hours after antacids.",See Summary
12,Lapatinib,Ambrisentan,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ambrisentan is metabolised by glucuronidation via UGTs 1A3, 1A9 and 2B7, and to a lesser extent by CYP3A4 and CYP2C19. Ambrisentan is also a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of orally administered ambrisentan may increase. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with ambrisentan. If coadministration appears necessary, monitoring of blood pressure is recommended.",See Summary
13,Lapatinib,Amikacin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amikacin is eliminated by glomerular filtration. Lapatinib is unlikely to interfere with this elimination pathway.,See Summary
14,Lapatinib,Amiloride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amiloride is eliminated unchanged in the kidney. In vitro data indicate that amiloride is a substrate of OCT2. Lapatinib is unlikely to affect this elimination pathway.,See Summary
15,Lapatinib,Amiodarone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Amiodarone is metabolised by CYP3A4 and CYP2C8. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with amiodarone. Lapatinib is also an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. Caution should be exercised and a dose reduction of amiodarone should be considered. Monitor closely for amiodarone toxicity. Furthermore, the major metabolite of amiodarone, desethylamiodarone, is an inhibitor of CYPs 3A4 (weak), 2C9 (moderate), 2D6 (moderate), 2C19 (weak), 1A1 (strong) and 2B6 (moderate). Concentrations of lapatinib may increase due to inhibition of CYP3A4 and CYP2C19. The clinical relevance of this interaction is unknown. Due to the long half-life of amiodarone, interactions can be observed for several months after discontinuation of amiodarone. In addition, lapatinib and amiodarone may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
16,Lapatinib,Amisulpride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amisulpride is weakly metabolised and is primarily renally eliminated (possibly via OCT). Lapatinib is unlikely to interfere with this elimination pathway.,See Summary
17,Lapatinib,Amitriptyline,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Amitriptyline is metabolised predominantly by CYP2D6 and CYP2C19, with a small proportion metabolised by CYPs 3A4, 1A2 and 2C9. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway, no clinically relevant effect on amitriptyline exposure is expected. However, lapatinib and amitriptyline may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended. ",See Summary
18,Lapatinib,Amlodipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Amlodipine is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered amlodipine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with amlodipine. Care should be taken when orally administered amlodipine is coadministered with lapatinib. Monitoring for amlodipine toxicity is recommended.",See Summary
19,Lapatinib,Amoxicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Amoxicillin is mainly excreted in the urine by glomerular filtration and tubular secretion. In vitro data indicate that amoxicillin is a substrate of OAT3. Lapatinib is unlikely to interfere with this elimination pathway.,See Summary
20,Lapatinib,Amphotericin B,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Amphotericin B is not appreciably metabolised but is eliminated to a large extent in the bile. Lapatinib does not interfere with this elimination pathway. However, the European SPC for amphotericin B states that concomitant use of amphotericin B and antineoplastic agents can increase the risk of renal toxicity, bronchospasm and hypotension. Furthermore, lapatinib and amphotericin B may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
21,Lapatinib,Ampicillin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Renal clearance of ampicillin occurs partly by glomerular filtration and partly by tubular secretion. About 20-40% of an oral dose may be excreted unchanged in the urine in 6 hours. After parenteral use about 60-80% is excreted in the urine within 6 hours. Lapatinib is unlikely to interfere with elimination pathway.,See Summary
22,Lapatinib,Anidulafungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Anidulafungin is not metabolised hepatically but undergoes chemical degradation at physiological temperatures. Lapatinib is unlikely to interfere with this metabolic pathway.,See Summary
23,Lapatinib,Antacids,"
Potential Weak Interaction
","
Very Low
"," Coadministration has not been studied. Antacids are not metabolised by CYPs. Lapatinib is unlikely to interfere with this metabolic pathway. The solubility of lapatinib is pH-dependent. Pre-treatment with a proton pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 26%. If coadministration is clinically necessary, lapatinib should be administered at least 2 hours before or 4 hours after antacids.",See Summary
24,Lapatinib,Apixaban,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Apixaban is metabolised by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8, 2C9 and 2C19. Apixaban is also a substrate of P-gp and BCRP. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of apixaban may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Similar effects may occur with apixaban. Care should be taken when orally administered apixaban is coadministered with lapatinib. Monitoring for apixaban toxicity and anti-Xa activity is recommended, if available.",See Summary
25,Lapatinib,Aprepitant,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of aprepitant may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with aprepitant. Therefore, care should be taken when orally administered aprepitant is coadministered with lapatinib. Monitoring for aprepitant toxicity is recommended. Furthermore, during treatment aprepitant is a moderate inhibitor of CYP3A4 and may increase lapatinib concentrations. Coadministration should be approached with caution. After treatment aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Concentrations of aprepitant may decrease due to CYP3A4 induction, but a clinically relevant interaction is unlikely. ",See Summary
26,Lapatinib,Aripiprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Aripiprazole is metabolised by CYP3A4 and CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered aripiprazole may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam by 45%. A similar effect may occur with aripiprazole. Care should be taken when orally administered aripiprazole is coadministered with lapatinib. Monitoring for aripiprazole toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant interaction is expected.",See Summary
27,Lapatinib,Asenapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Asenapine is metabolised by glucuronidation (UGT1A4) and oxidative metabolism (CYPs 1A2 (major), 3A4 (minor) and 2D6 (minor)). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered asenapine may increase. However, since CYP3A4 is a minor pathway, a clinically relevant interaction is not expected.",See Summary
28,Lapatinib,Astemizole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Astemizole is metabolised by CYPs 2D6, 2J2 and 3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered astemizole may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with astemizole. Care should be taken when orally administered astemizole is coadministered with lapatinib. Monitoring for astemizole toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), a clinically relevant effect on astemizole exposure is not expected. Furthermore, lapatinib and astemizole may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
29,Lapatinib,Atenolol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Atenolol is mainly eliminated unchanged in the kidney, predominantly by glomerular filtration. Lapatinib is unlikely to interfere with this elimination pathway.",See Summary
30,Lapatinib,Atorvastatin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Atorvastatin is metabolised by CYP3A4 and is a substrate of P-gp and OATP1B1. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib also inhibits P-gp and OATP1B1 (in vitro). Concentrations of atorvastatin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Similar effects may occur after coadministration with atorvastatin. If coadministration is unavoidable, monitor for atorvastatin toxicity.",See Summary
31,Lapatinib,Azathioprine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Azathioprine is converted to 6-mercaptopurine which is metabolised analogously to natural purines. Lapatinib does not interfere with this metabolic pathway.,See Summary
32,Lapatinib,Azithromycin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Azithromycin is mainly eliminated via biliary excretion with animal data suggesting this may occur via P-gp and MRP2. Lapatinib is an inhibitor of P-gp and may increase concentrations of azithromycin. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC 80%. A similar effect may occur with azithromycin. As the clinical relevance of this interaction is unknown, monitoring for azithromycin toxicity may be required. Azithromycin is also an inhibitor of P-gp, but the clinical relevance of P-gp inhibition by azithromycin is unknown. Lapatinib is not a substrate of P-gp. However, lapatinib and azithromycin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
33,Lapatinib,Beclometasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Beclometasone is a pro-drug which is not metabolised by CYP450, but is hydrolysed via esterase enzymes to the highly active metabolite beclometasone -17-monopropionate. Lapatinib does not interact with this metabolic pathway. ",See Summary
34,Lapatinib,Bedaquiline,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Bedaquiline is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered bedaquiline may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with bedaquiline. Care should be taken when orally administered bedaquiline is coadministered with lapatinib. Monitoring for bedaquiline toxicity is recommended. Furthermore, lapatinib and bedaquiline may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
35,Lapatinib,Bendroflumethiazide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism (70%) and excreted unchanged in the urine (30%) via OAT1 and OAT3. In vitro data indicate that bendroflumethiazide inhibits these renal transporters but a clinically relevant interaction is unlikely in the range of observed clinical concentrations. In addition, there is no evidence that bendroflumethiazide inhibits or induces CYP450 enzymes and is unlikely to affect lapatinib.",See Summary
36,Lapatinib,Bepridil,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Bepridil is metabolised by CYP2D6 (major) and CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered bepridil may increase. Since CYP3A4 is a minor pathway, a pharmacokinetic interaction is not expected. However, lapatinib and bepridil may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, ECG monitoring is recommended.",See Summary
37,Lapatinib,Betamethasone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Betamethasone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered betamethasone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45% A similar effect may occur with betamethasone. Care should be taken when orally administered betamethasone is coadministered with lapatinib. Monitoring for betamethasone toxicity is recommended. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
38,Lapatinib,Bezafibrate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Half of a bezafibrate dose is eliminated unchanged in the urine. In vitro data suggest that bezafibrate inhibits the renal transporter OAT1. Lapatinib is unlikely to interfere with this elimination pathway.,See Summary
39,Lapatinib,Bisacodyl,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bisacodyl is converted to an active metabolite by intestinal and bacterial enzymes. Absorption from the gastrointestinal tract is minimal and the small amount absorbed is excreted in the urine as the glucuronide. Lapatinib is unlikely to interfere with this metabolic pathway.,See Summary
40,Lapatinib,Bisoprolol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Bisoprolol is partly metabolised by CYP3A4 and CYP2D6, and partly eliminated unchanged in the urine. Bisoprolol is also a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of bisoprolol may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Similar effects may occur with bisoprolol. Monitoring of blood pressure is recommended.",See Summary
41,Lapatinib,Bosentan,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Bosentan is a substrate of CYP3A4 and CYP2C9. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic lapatinib. Concentrations of orally administered bosentan may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with bosentan. Care should be taken when orally administered bosentan is coadministered with lapatinib. Monitoring for bosentan toxicity is recommended. Bosentan is also a weak inducer of CYP3A4 and CYP2C9 and may decrease lapatinib exposure. In a phase III study, imatinib (a CYP3A4 substrate) concentrations, on average, decreased by 33% (95% CI 18%, 45%) in the presence of bosentan. Imatinib and lapatinib are both mainly metabolised by CYP3A4 and a similar result may occur with lapatinib. If coadministration is necessary, close monitoring of lapatinib efficacy is required. Monitor lapatinib plasma concentrations, if available.",See Summary
42,Lapatinib,Bromazepam,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bromazepam undergoes oxidative biotransformation. Interaction studies indicate that CYP3A4 plays a minor role in bromazepam metabolism, but other cytochromes such as CYP2D6 or CYP1A2 may play a role. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway, no clinically relevant effect on bromazepam exposure is expected.",See Summary
43,Lapatinib,Budesonide,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Budesonide is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered budesonide may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with budesonide. Care should be taken when orally administered budesonide is coadministered with lapatinib. Monitoring for budesonide toxicity is recommended. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
44,Lapatinib,Buprenorphine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Buprenorphine undergoes both N-dealkylation to form norbuprenorphine (via CYP3A4) and glucuronidation (via UGT2B7 and UGT1A1). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. For the oral formulation of buprenorphine, lapatinib may increase concentrations of buprenorphine. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with buprenorphine. For administration routes other than oral (e.g. i.v. drugs), a clinically relevant interaction is not expected. Lapatinib is also an in vitro inhibitor of UGT1A1 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for buprenorphine toxicity may be required.",See Summary
45,Lapatinib,Bupropion,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bupropion is primarily metabolised by CYP2B6 and is a strong inhibitor of CYP2D6. Lapatinib does not interact with this metabolic pathway.,See Summary
46,Lapatinib,Buspirone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Buspirone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered buspirone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with buspirone. Care should be taken when orally administered buspirone is coadministered with lapatinib. Monitoring for buspirone toxicity is recommended.",See Summary
47,Lapatinib,Calcium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcium is eliminated through faeces, urine and sweat. Lapatinib does not interfere with this elimination pathway.",See Summary
48,Lapatinib,Candesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Candesartan is mainly eliminated unchanged via urine and bile. Lapatinib does not interact with this elimination pathway.,See Summary
49,Lapatinib,Capreomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capreomycin is predominantly excreted via the kidneys as unchanged drug. Lapatinib does not interfere with this elimination pathway.,See Summary
50,Lapatinib,Captopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Captopril is largely excreted in the urine by OAT1. Lapatinib is unlikely to interfere with this elimination pathway.,See Summary
51,Lapatinib,Carbamazepine,"
Do Not Coadminister
","
Very Low
","Coadministration should be avoided. Carbamazepine is primarily metabolised by CYP3A4 and to a lesser extent by CYP2C8. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of carbamazepine may increase, but since carbamazepine is a strong CYP3A4 inducer itself, no clinically relevant effect on carbamazepine exposure is expected. Lapatinib also inhibits CYP2C8 in vitro at clinically relevant concentrations, but since CYP2C8 is a minor pathway, this is unlikely to lead to a clinically relevant effect. However, carbamazepine is an inducer of CYPs 2C8 (strong), 2C9 (strong), 3A4 (strong), 1A2 (weak), 2B6 and UGT1A1. Concentrations of lapatinib may decrease due to induction of CYP3A4 and CYP2C8. In healthy volunteers, coadministration of lapatinib and carbamazepine decreased systemic exposure of lapatinib by approximately 72%. Therefore, coadministration should be avoided. Selection of an alternative concomitant medication with no or minimal enzyme induction potential is recommended. If patients must be co-treated with carbamazepine, pharmacokinetic studies suggest titrating the dose of lapatinib up by a factor of 3-4 based on tolerability. If carbamazepine is discontinued the lapatinib dose should be reduced to the indicated dose. Monitor lapatinib plasma concentrations, if available.",See Summary
52,Lapatinib,Carvedilol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7, and metabolism via CYP2D6 and to a lesser extent by CYPs 2C9 and 1A2. Carvedilol is also a substrate of P-gp. Lapatinib is an in vitro inhibitor of UGT1A1 at clinically relevant concentrations. Lapatinib is also an inhibitor of P-gp and may increase concentrations of carvedilol. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with carvedilol. Monitoring of blood pressure is recommended.",See Summary
53,Lapatinib,Caspofungin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Caspofungin undergoes spontaneous chemical degradation and metabolism via a non CYP-mediated pathway. Lapatinib does not interact with this metabolic pathway. ,See Summary
54,Lapatinib,Cefalexin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefalexin is predominantly renally eliminated unchanged by glomerular filtration and tubular secretion via OAT1 and MATE1. Lapatinib does not interfere with this elimination pathway.,See Summary
55,Lapatinib,Cefazolin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefazolin is predominantly excreted unchanged in the urine, mainly by glomerular filtration with some renal tubular secretion via OAT3. Lapatinib does not interfere with this elimination pathway.",See Summary
56,Lapatinib,Cefixime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefixime is renally excreted predominantly by glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
57,Lapatinib,Cefotaxime,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cefotaxime is partially metabolised by non-specific esterases. Most of a dose of cefotaxime is excreted in the urine - about 60% as unchanged drug and a further 24% as desacetyl-cefotaxime, an active metabolite. In vitro studies indicate that OAT3 participates in the renal elimination of cefotaxime. Lapatinib does not interfere with this elimination pathway.",See Summary
58,Lapatinib,Ceftazidime,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftazidime is excreted predominantly by renal glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
59,Lapatinib,Ceftriaxone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being excreted in the urine predominantly by glomerular filtration and the remainder via the biliary and intestinal tracts. Lapatinib does not interfere with this elimination pathway.",See Summary
60,Lapatinib,Celecoxib,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Celecoxib is primarily metabolised by CYP2C9. Lapatinib does not inhibit or induce CYP2C9. ,See Summary
61,Lapatinib,Cetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cetirizine is only metabolised to a limited extent but is eliminated unchanged in the urine through both glomerular filtration and tubular secretion. In vitro data indicate that cetirizine inhibits OCT2. Lapatinib is unlikely to interact with this elimination pathway.,See Summary
62,Lapatinib,Chloramphenicol,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Chloramphenicol is predominantly glucuronidated. In vitro studies have shown that chloramphenicol can inhibit metabolism mediated by CYPs 3A4 (strong), 2C19 (strong) and 2D6 (weak). Concentrations of lapatinib may increase due to CYP3A4 inhibition, increasing the risk of adverse events. As the clinical relevance of this interaction is unknown, close monitoring is recommended. Ocular use: Although chloramphenicol is systemically absorbed when used topically in the eye, the absorbed concentrations are unlikely to cause a clinically significant interaction. ",See Summary
63,Lapatinib,Chlordiazepoxide,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Chlordiazepoxide is extensively metabolised by CYP3A4, but does not inhibit or induce cytochromes. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered chlordiazepoxide may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with chlordiazepoxide. Care should be taken when orally administered chlordiazepoxide is coadministered with lapatinib. Monitoring for chlordiazepoxide toxicity is recommended.",See Summary
64,Lapatinib,Chlorphenamine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorphenamine is predominantly metabolised in the liver via CYP2D6. Lapatinib does not inhibit or induce CYP2D6.,See Summary
65,Lapatinib,Chlorpromazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Chlorpromazine is metabolised mainly by CYP2D6, but also by CYP1A2. Lapatinib does not inhibit or induce CYP2D6 or CYP1A2. However, lapatinib and chlorpromazine may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
66,Lapatinib,Chlortalidone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlortalidone is mainly excreted unchanged in the urine and faeces. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Lapatinib is unlikely to interfere with this elimination pathway.,See Summary
67,Lapatinib,Ciclosporin (Cyclosporine),"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Ciclosporin is a substrate of CYP3A4 and P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Coadministration should be approached with caution. Monitor for ciclosporin toxicity and plasma concentrations, if available. Furthermore, ciclosporin is an inhibitor of CYP3A4 and OATP1B1. Concentrations of lapatinib may increase due to CYP3A4 inhibition. The clinical relevance of this interaction is unknown. No a priori dosage adjustment is recommended for lapatinib, but close monitoring is recommended. Monitor lapatinib plasma concentrations, if available.",See Summary
68,Lapatinib,Cilazapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cilazapril is mainly eliminated unchanged by the kidneys. Lapatinib does not interfere with this elimination pathway.,See Summary
69,Lapatinib,Cimetidine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Cimetidine is metabolised by CYP450 enzymes. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. Concentrations of cimetidine may increase but the clinical significance of CYP3A4 and CYP2C8 inhibition is unknown. Furthermore, in vitro data indicate that cimetidine inhibits OAT1 and OCT2 but at concentrations much higher than the observed clinical concentrations. Lapatinib does not interact with this pathway. Cimetidine is also a weak inhibitor of CYPs 3A4, 1A2, 2D6 and 2C19. Concentrations of lapatinib may increase due to inhibition of CYP3A4 and CYP2C19. The solubility of lapatinib is pH-dependent. Pre-treatment with a proton pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 26%. A similar effect may occur with cimetidine. A decrease in exposure may lead to a decrease in lapatinib efficacy. If coadministration is unavoidable, monitor lapatinib efficacy and plasma concentrations, if available.",See Summary
70,Lapatinib,Ciprofloxacin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Ciprofloxacin is primarily eliminated unchanged in the kidneys by glomerular filtration and tubular secretion via OAT3. Ciprofloxacin is also metabolised and partially cleared through the bile and intestine. Lapatinib does not interact with this pathway. However, ciprofloxacin is a weak to moderate inhibitor of CYP3A4 and a strong inhibitor of CYP1A2. Concentrations of lapatinib may increase due to moderate inhibition of CYP3A4. Coadministration should be approached with caution. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for lapatinib toxicity and monitor lapatinib plasma concentrations, if available. Furthermore, lapatinib and ciprofloxacin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
71,Lapatinib,Cisapride,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Cisapride is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of cisapride may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with cisapride. Care should be taken when orally administered cisapride is coadministered with lapatinib. Monitoring for cisapride toxicity is recommended. Furthermore, lapatinib and cisapride may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
72,Lapatinib,Citalopram,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Citalopram is metabolised by CYPs 2C19 (38%), 2D6 (31%) and 3A4 (31%). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered citalopram may increase. However, since CYP3A4 is a minor pathway, no clinically relevant effect on citalopram exposure is expected. Furthermore, lapatinib and citalopram may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
73,Lapatinib,Clarithromycin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Clarithromycin is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered clarithromycin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with clarithromycin. Monitoring for clarithromycin toxicity is recommended. Furthermore, clarithromycin is an inhibitor of CYP3A4 (strong) and P-gp, and may increase concentrations of lapatinib. In healthy volunteers, coadministration of lapatinib and ketoconazole, a strong CYP3A4 inhibitor, increased lapatinib exposure by approximately 3.6-fold. A similar effect may occur with clarithromycin. Therefore, coadministration should be avoided. If coadministration is unavoidable, a dose reduction of 50-66% for lapatinib is recommended based on pharmacokinetic studies. Monitor closely for lapatinib toxicity, including ECG. Monitor lapatinib plasma concentrations, if available.",See Summary
74,Lapatinib,Clavulanic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clavulanic acid is extensively metabolised (likely non-CYP mediated pathway) and excreted in the urine by glomerular filtration. Lapatinib does not interfere with this metabolic pathway.,See Summary
75,Lapatinib,Clemastine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clemastine is predominantly metabolised in the liver via CYP2D6. Lapatinib does not inhibit or induce CYP2D6.,See Summary
76,Lapatinib,Clindamycin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Clindamycin is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered clindamycin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with clindamycin. Care should be taken when orally administered clindamycin is coadministered with lapatinib. Monitoring for clindamycin toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant interaction is expected. Furthermore, in vitro data suggest that clindamycin is a CYP3A4 inhibitor, and may increase concentrations of lapatinib. The clinical relevance of this interaction is unknown. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. Monitoring for lapatinib toxicity may be required and, if available, monitor lapatinib plasma concentrations.",See Summary
77,Lapatinib,Clobetasol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of clobetasol.,See Summary
78,Lapatinib,Clofazimine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Clofazimine is largely excreted unchanged in the faeces. Lapatinib does not interfere with this elimination pathway. However, in vitro data suggest that clofazimine is a CYP3A4 inhibitor, and may increase concentrations of lapatinib. The clinical relevance of this interaction is unknown. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. Monitoring for lapatinib toxicity may be required and, if available, monitor lapatinib plasma concentrations. Furthermore, lapatinib and clofazimine may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
79,Lapatinib,Clofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clofibrate is hydrolysed to an active metabolite, clofibric acid. Excretion of clofibric acid glucuronide is possibly performed via OAT1. Lapatinib does not interfere with this elimination pathway.",See Summary
80,Lapatinib,Clomipramine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Clomipramine is metabolised by CYPs 3A4, 1A2 and 2C19 to desmethylclomipramine, an active metabolite which has a higher activity than the parent drug. Clomipramine and desmethylclomipramine are both metabolised by CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered clomipramine may increase and thus concentrations of desmethylclomipramine may decrease. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with clomipramine. Care should be taken when orally administered clomipramine is coadministered with lapatinib. Monitoring for toxicity is recommended. Furthermore, lapatinib and clomipramine may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
81,Lapatinib,Clonidine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 70% of administered clonidine is excreted in the urine, mainly in the form of the unchanged parent drug (40-60% of the dose). Clonidine is a weak inhibitor of OCT2 but is unlikely to interact with the elimination of lapatinib. Lapatinib does not interfere with this pathway.",See Summary
82,Lapatinib,Clopidogrel,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Clopidogrel is a prodrug and is converted to its active metabolite mainly through CYP2C19 with CYPs 3A4, 2B6 and 1A2 playing a minor role. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered clopidogrel may increase and thus concentrations of the active metabolite may decrease. Care should be taken when orally administered clopidogrel is coadministered with lapatinib. Monitoring for both clopidogrel toxicity and efficacy is recommended. Furthermore, clopidogrel is an inhibitor of CYP2C8 (strong), CYP2B6 (weak) and of CYP2C9 (in vitro) at high concentrations. The clinical relevance of CYP2C9 inhibition is unknown. Since CYP2C8 is a minor pathway in lapatinib metabolism, a clinically relevant effect on lapatinib exposure is not expected.",See Summary
83,Lapatinib,Clorazepate,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Clorazepate is rapidly converted to nordiazepam which is then metabolised to oxazepam by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered clorazepate may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with clorazepate. Furthermore, oxazepam is mainly glucuronidated. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. The clinical relevance of UGT inhibition is unknown. Care should be taken when orally administered clorazepate is coadministered with lapatinib. Monitoring for clorazepate and oxazepam toxicity is recommended.",See Summary
84,Lapatinib,Cloxacillin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cloxacillin is metabolised to a limited extent, and the unchanged drug and metabolites are excreted in the urine by glomerular filtration and renal tubular secretion. Lapatinib does not interact with this elimination pathway.",See Summary
85,Lapatinib,Clozapine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Clozapine is metabolised mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2C19 and CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered clozapine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with clozapine. If coadministration is unavoidable, care should be taken when orally administered clozapine is coadministered with lapatinib. Monitoring for clozapine toxicity is recommended. Furthermore, lapatinib and clozapine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
86,Lapatinib,Codeine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Codeine is converted via CYP2D6 to morphine, an active metabolite with analgesic and opioid properties. Morphine is further metabolised by conjugation with glucuronic acid to morphine-3-glucuronide (inactive) and morphine-6-glucuronide (active). Codeine is converted via CYP3A4 to norcodeine, an inactive metabolite. The metabolite morphine is also a substrate of P-gp. Lapatinib is an in vitro inhibitor of UGT1A1 at clinically relevant concentrations, but a clinically significant interaction is unlikely since UGT1A1 is only a minor pathway. Lapatinib is also a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered codeine may increase but this is not considered to be clinically relevant. Furthermore, lapatinib is an inhibitor of P-gp and may increase concentrations of morphine. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur with morphine. Monitoring for morphine toxicity is recommended.",See Summary
87,Lapatinib,Colchicine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Colchicine is metabolised by CYP3A4 and is a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of colchicine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. Furthermore, coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Similar effects may occur with colchicine. Therefore, coadministration should be approached with caution. If coadministration is unavoidable, monitor closely for colchicine toxicity.",See Summary
88,Lapatinib,Cycloserine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cycloserine is predominantly renally excreted via glomerular filtration. Lapatinib does not interact with this elimination pathway.,See Summary
89,Lapatinib,Dabigatran,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Dabigatran is a substrate of P-gp and is renally excreted. Lapatinib is an inhibitor of P-gp and may increase concentrations of dabigatran. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur with dabigatran. Therefore, caution should be exercised and a dose reduction of dabigatran should be considered. Monitoring of dabigatran toxicity and ecarine clotting time or diluted thrombin time is recommended, if available.",See Summary
90,Lapatinib,Dalteparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dalteparin is excreted largely unchanged via the kidneys. Lapatinib does not interfere with this elimination pathway. ,See Summary
91,Lapatinib,Dapsone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of dapsone is mainly by N-acetylation with a component of N-hydroxylation, and is via multiple CYP450 enzymes. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. However, since multiple CYP enzymes are involved, a clinically significant interaction is unlikely. ",See Summary
92,Lapatinib,Desipramine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Desipramine is metabolised by CYP2D6. Lapatinib does not inhibit or induce CYP2D6. However, lapatinib and desipramine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
93,Lapatinib,Desogestrel,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Desogestrel is a prodrug which is activated to etonogestrel by CYP2C9 (and possibly CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of etonogestrel may increase concentrations. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with etonogestrel. Care should be taken when orally administered desogestrel is coadministered with lapatinib. Monitoring for desogestrel toxicity may be required. ",See Summary
94,Lapatinib,Dexamethasone,"
Potential Interaction
","
Very Low
","Coadministration should be approached with caution. Dexamethasone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered dexamethasone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with dexamethasone. Care should be taken when orally administered dexamethasone is coadministered with lapatinib. Monitoring for dexamethasone toxicity may be required. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant interaction is expected. Furthermore, dexamethasone is a known weak inducer of CYP3A4 and may decrease lapatinib plasma concentrations. The clinical relevance of this interaction is unknown as the induction of CYP3A4 by dexamethasone has yet to be established. In patients, coadministration of lapatinib and dexamethasone increased the risk of developing hepatotoxicity by around 5 times, compared to lapatinib alone. If coadministration is unavoidable, closely monitor lapatinib efficacy and symptoms of hepatotoxicity. Monitor lapatinib plasma concentrations, if available.",See Summary
95,Lapatinib,Dextropropoxyphene,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Dextropropoxyphene is mainly metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of dextropropoxyphene may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with dextropropoxyphene. Care should be taken when orally administered dextropropoxyphene is coadministered with lapatinib. Monitoring for dextropropoxyphene toxicity is recommended.",See Summary
96,Lapatinib,Diamorphine (diacetylmorphine),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Diamorphine is rapidly metabolised by sequential deacetylation to morphine which is then mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Morphine is also a substrate of P-gp. Lapatinib is an in vitro inhibitor of UGT1A1 at clinically relevant concentrations, and may increase morphine concentrations. A clinically relevant interaction is unlikely as UGT1A1 is only a minor pathway in morphine metabolism. However, lapatinib is also an inhibitor of P-gp. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur with morphine. Monitoring for morphine toxicity is recommended.",See Summary
97,Lapatinib,Diazepam,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Diazepam is metabolised to nordiazepam (by CYP3A4 and CYP2C19) and to temazepam (mainly by CYP3A4). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered diazepam may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with diazepam. Furthermore, temazepam is mainly glucuronidated. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. The clinical relevance of this interaction is unknown. Care should be taken when orally administered diazepam is coadministered with lapatinib. Monitoring for diazepam and temazepam toxicity is recommended.",See Summary
98,Lapatinib,Diclofenac,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Diclofenac is partly glucuronidated by UGT2B7 and partly oxidised by CYP2C9. Lapatinib does not inhibit or induce UGT2B7 or CYP2C9. ,See Summary
99,Lapatinib,Digoxin,"
Potential Interaction
","
Very Low
","Coadministration should be approached with caution. Digoxin is renally eliminated via OATP4C1 and P-gp. Lapatinib is an inhibitor of P-gp and may increase digoxin concentrations. Coadministration of lapatinib and digoxin increased digoxin AUC by 80%. It is recommended that the lowest possible dose of digoxin should initially be given to patients on lapatinib. The digoxin dose should be carefully titrated to obtain the desired clinical effect while assessing the overall clinical state of the patient. Monitor digoxin concentrations, if available.",See Summary
100,Lapatinib,Dihydrocodeine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Dihydrocodeine undergoes predominantly direct glucuronidation, with CYP3A4 mediated metabolism accounting for only 5-10% of the overall metabolism. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for dihydrocodeine toxicity may be required. Furthermore, lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is only a minor pathway in dihydrocodeine metabolism, a clinically relevant effect due to CYP3A4 inhibtion is not expected.",See Summary
101,Lapatinib,Diltiazem,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Diltiazem is metabolised by CYP3A4 and CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of diltiazem may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with diltiazem. Care should be taken when orally administered diltiazem is coadministered with lapatinib. Monitoring for diltiazem toxicity is recommended. For administration routes other than oral (e.g. rectal drugs), no clinically relevant effect on diltiazem exposure is expected. Furthermore, diltiazem is a moderate inhibitor of CYP3A4 and may increase lapatinib exposure. Coadministration should be approached with caution. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for lapatinib toxicity. Monitor lapatinib plasma concentrations, if available.",See Summary
102,Lapatinib,Diphenhydramine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Diphenhydramine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 1A2, 2C9 and 2C19. Lapatinib does not inhibit or induce CYPs 2D6, 1A2, 2C9 or 2C19. Diphenhydramine is also a weak inhibitor of CYP2D6. Lapatinib is not metabolised by CYP2D6. However, lapatinib and diphenhydramine may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended. ",See Summary
103,Lapatinib,Dipyridamole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Dipyridamole is glucuronidated by many UGTs, specifically those of the UGT1A subfamily. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for dipyridamole toxicity may be required.",See Summary
104,Lapatinib,Disopyramide,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Disopyramide is metabolised by CYP3A4 (25%) and 50% of the drug is eliminated unchanged in the urine. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered disopyramide may increase but since CYP3A4 is a minor pathway, a pharmacokinetic interaction is unlikely. However, lapatinib and disopyramide may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
105,Lapatinib,Dolasetron,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Dolasetron is converted by carbonyl reductase to its active metabolite, hydrodolasetron, which is mainly glucuronidated (60%) and metabolised by CYP2D6 (10-20%) and CYP3A4 (<1%). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway, no clinically relevant effect on dolasetron exposure is expected. However, lapatinib and dolasetron may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
106,Lapatinib,Domperidone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Domperidone is mainly metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered domperidone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with domperidone. If coadministration is unavoidable, monitoring for domperidone toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant effect on domperidone exposure is expected. However, lapatinib and domperidone may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
107,Lapatinib,Dopamine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dopamine is metabolised in the liver, kidneys, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase to inactive compounds. About 25% of a dose of dopamine is metabolised to norepinephrine within the adrenergic nerve terminals. There is little potential for dopamine to affect the disposition of lapatinib, or to be affected if coadministered with lapatinib.",See Summary
108,Lapatinib,Doxazosin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Doxazosin is metabolised mainly by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered doxazosin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with doxazosin. Care should be taken when orally administered doxazosin is coadministered with lapatinib. Monitoring for doxazosin toxicity is recommended.",See Summary
109,Lapatinib,Doxepin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxepin is metabolised to nordoxepin (a metabolite with comparable pharmacological activity as the parent compound) mainly by CYP2C19. Doxepin and nordoxepin are both metabolised by CYP2D6. Lapatinib does not inhibit or induce CYP2C19 or CYP2D6. ,See Summary
110,Lapatinib,Doxycycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Doxycycline is excreted in the urine and faeces as unchanged active substance. Between 40-60% of an administered dose can be accounted for in the urine. Lapatinib does not interact with this elimination pathway.,See Summary
111,Lapatinib,Dronabinol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dronabinol is mainly metabolised by CYP2C9 and to a lesser extent by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered dronabinol may increase. However, since CYP3A4 is a minor pathway, no clinically relevant effect on dronabinol exposure is expected.",See Summary
112,Lapatinib,Drospirenone,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drospirenone is metabolised to a minor extent via CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of drospirenone may increase. However, since CYP3A4 is a minor pathway, no clinically relevant interaction is expected.",See Summary
113,Lapatinib,Dulaglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dulaglutide is degraded by endogenous endopeptidases. Dulaglutide delays gastric emptying and could possibly decrease the absorption rate of concomitantly administered oral drugs. The clinical relevance of delayed absorption is considered to be limited.,See Summary
114,Lapatinib,Duloxetine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Duloxetine is metabolised by CYP2D6 and CYP1A2. Lapatinib does not inhibit or induce CYP2D6 or CYP1A2. ,See Summary
115,Lapatinib,Dutasteride,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Dutasteride is mainly metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered dutasteride may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with dutasteride. Care should be taken when orally administered dutasteride is coadministered with lapatinib. Monitoring for dutasteride toxicity is recommended.",See Summary
116,Lapatinib,Dydrogesterone,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Dydrogesterone is metabolised to dihydrodydrogesterone (possibly via CYP3A4). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of dydrogesterone may increase. The clinical relevance of this interaction is unknown. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with dydrogesterone. Care should be taken when orally administered dydrogesterone is coadministered with lapatinib. Monitoring for dydrogesterone toxicity may be required.",See Summary
117,Lapatinib,Edoxaban,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Edoxaban is partially metabolised by CYP3A4 (<10%) and is transported via P-gp. Lapatinib is an inhibitor of P-gp and may increase concentrations of edoxaban. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with edoxaban. Caution should be exercised and a dose reduction of edoxaban should be considered. Monitor for edoxaban toxicity and anti-Xa activity, if available. ",See Summary
118,Lapatinib,Eltrombopag,"
Potential Interaction
","
Very Low
",Coadministration has not been studied but should be approached with caution. Eltrombopag is metabolised by cleavage conjugation (via UGT1A1 and UGT1A3) and oxidation (via CYP1A2 and CYP2C8). Lapatinib is an in vitro inhibitor of UGT1A1 and CYP2C8 at clinically relevant concentrations. The clinical relevance of this interaction is unknown. Caution should be exercised and a dose reduction of eltrombopag should be considered. Monitor closely for eltrombopag toxicity.,See Summary
119,Lapatinib,Enalapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enalapril is hydrolysed to enalaprilat which is renally eliminated (possibly via OATs). Lapatinib is unlikely to interfere with this metabolic pathway.,See Summary
120,Lapatinib,Enoxaparin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Enoxaparin does not undergo cytochrome metabolism but is desulphated and depolymerised in the liver, and is predominantly renally excreted. Lapatinib does not interact with this metabolic pathway.",See Summary
121,Lapatinib,Eprosartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eprosartan is largely excreted in bile and urine as unchanged drug. Lapatinib does not interfere with this elimination pathway.,See Summary
122,Lapatinib,Ertapenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ertapenem is mainly eliminated through the kidneys by glomerular filtration with tubular secretion playing a minor role. Lapatinib does not interfere with this elimination pathway.,See Summary
123,Lapatinib,Erythromycin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Erythromycin is a substrate of CYP3A4 and P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of erythromycin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Similar effects may occur with erythromycin. Therefore, caution should be exercised and a dose reduction of erythromycin should be considered. Monitor for erythromycin toxicity. Erythromycin is also an inhibitor of CYP3A4 (moderate) and P-gp, and may increase concentrations of lapatinib. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for lapatinib toxicity. Monitor lapatinib plasma concentrations, if available. Lapatinib and erythromycin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
124,Lapatinib,Escitalopram,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Escitalopram is metabolised by CYPs 2C19 (37%), 2D6 (28%) and 3A4 (35%) to form N-desmethylescitalopram. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered escitalopram may increase. Since CYP3A4 is a minor pathway, no clinically relevant effect on escitalopram exposure is expected. However, lapatinib and escitalopram may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
125,Lapatinib,Esomeprazole,"
Potential Weak Interaction
","
Moderate
","In patients, pre-treatment with esomeprazole decreased lapatinib AUC by 26%. A decrease in exposure may lead to a decrease in lapatinib efficacy. If coadministration is unavoidable, monitor lapatinib efficacy. Monitoring for lapatinib plasma concentrations should be considered. Furthermore, esomeprazole is metabolised by CYP2C19 and CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of esomeprazole may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with esomeprazole. Care should be taken when orally administered esomeprazole is coadministered with lapatinib. Monitoring for esomeprazole toxicity may be required. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant interaction is expected. Esomeprazole is an inhibitor of CYP2C19. Lapatinib is not a substrate of CYP2C19.",See Summary
126,Lapatinib,Estazolam,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Estazolam is metabolised to its major metabolite 4-hydroxyestazolam via CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered estazolam may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with estazolam. Care should be taken when orally administered estazolam is coadministered with lapatinib. Monitoring for estazolam toxicity is recommended.",See Summary
127,Lapatinib,Estradiol,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Estradiol is metabolised by CYP3A4, CYP1A2 and is glucuronidated. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of estradiol may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with estradiol. Furthermore, lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations, but the clinical significance of UGT inhibition is unknown. Care should be taken when estradiol is coadministered with lapatinib. Monitoring for estradiol toxicity may be required.",See Summary
128,Lapatinib,Ethambutol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethambutol is partly metabolised by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and urine (50%). Lapatinib does not interact with this metabolic pathway.,See Summary
129,Lapatinib,Ethinylestradiol,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Ethinylestradiol undergoes oxidation (CYP3A4>CYP2C9), sulfation and glucuronidation (UGT1A1). Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations, but the clinical relevance of UGT inhibition is unknown. Lapatinib is also a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of ethinylestradiol may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with ethinylestradiol. Care should be taken when ethinylestradiol is coadministered with lapatinib. Monitoring for ethinylestradiol toxicity may be required.",See Summary
130,Lapatinib,Ethionamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ethionamide is extensively metabolised in the liver, animal studies suggest involvement of flavin-containing monooxygenases. Lapatinib does not interfere with this metabolic pathway. ",See Summary
131,Lapatinib,Etonogestrel,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Etonogestrel is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. However, since etonogestrel is not orally administered, a clinically relevant interaction is unlikely.",See Summary
132,Lapatinib,Everolimus (Immunosuppressant),"
No Interaction Expected
","
Moderate
","Everolimus is mainly metabolised by CYP3A4 and is a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of everolimus may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. Furthermore, lapatinib is an inhibitor of P-gp. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Similar effects may occur after coadministration with everolimus. However, in patients coadministration of lapatinib and everolimus resulted in a 25% increase in everolimus exposure. The exposure of lapatinib was unchanged. Coadministration was well tolerated.",See Summary
133,Lapatinib,Exenatide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Exenatide is cleared mainly by glomerular filtration. Exenatide delays gastric emptying and could possibly decrease the absorption rate of concomitantly administered oral drugs. The clinical relevance of delayed absorption is considered to be limited.,See Summary
134,Lapatinib,Ezetimibe,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ezetimibe is glucuronidated by UGTs 1A1 and 1A3 and to a lesser extent by UGTs 2B15 and 2B7. Lapatinib is an in vitro inhibitor of UGT1A1 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for ezetimibe toxicity may be required.",See Summary
135,Lapatinib,Famotidine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Famotidine is excreted via OAT1/OAT3. Lapatinib does not inhibit or induce OAT1/OAT3. However, the solubility of lapatinib is pH-dependent. Pre-treatment with a proton pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 26%. A similar effect may occur with famotidine. A decrease in exposure may lead to a decrease in lapatinib efficacy. If coadministration is unavoidable, monitor lapatinib efficacy and lapatinib plasma concentrations, if available.",See Summary
136,Lapatinib,Felodipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Felodipine is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of felodipine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with felodipine. Care should be taken when orally administered felodipine is coadministered with lapatinib. Monitoring for felodipine toxicity is recommended.",See Summary
137,Lapatinib,Fenofibrate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fenofibrate is hydrolysed to an active metabolite, fenofibric acid. In vitro data suggest that fenofibric acid inhibits OAT3. Lapatinib does not interact with this pathway.",See Summary
138,Lapatinib,Fentanyl,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fentanyl undergoes extensive CYP3A4 metabolism. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. However, since fentanyl is not orally administered, a clinically relevant interaction is not expected.",See Summary
139,Lapatinib,Fexofenadine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Fexofenadine is a substrate of P-gp. Lapatinib is an inhibitor of P-gp and may increase concentrations of fexofenadine. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur with fexofenadine. Monitoring for fexofenadine toxicity may be required.",See Summary
140,Lapatinib,Finasteride,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Finasteride is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered finasteride may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with finasteride. Care should be taken when orally administered finasteride is coadministered with lapatinib. Monitoring for finasteride toxicity is recommended.",See Summary
141,Lapatinib,Fish oils,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
142,Lapatinib,Flecainide,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Flecainide is metabolised mainly via CYP2D6, with a proportion (approximately 30%) of the parent drug also renally eliminated unchanged. Lapatinib does not interact with this metabolic pathway. However, lapatinib and flecainide may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
143,Lapatinib,Flucloxacillin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Flucloxacillin is mainly renally eliminated partly by glomerular filtration and partly by active secretion via OAT1. Lapatinib does not interact with this metabolic pathway. Flucloxacillin has been described as a CYP3A4 inducer and may decrease concentrations of lapatinib. However, the mechanism and clinical relevance of this interaction is unknown. No a priori dose adjustment for lapatinib is recommended. However, monitoring for decreased lapatinib efficacy and, if available, lapatinib plasma concentrations may be required.",See Summary
144,Lapatinib,Fluconazole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Fluconazole is cleared primarily by renal excretion. Lapatinib does not interfere with this elimination pathway. However, fluconazole is an inhibitor of CYPs 3A4 (moderate), 2C9 (moderate) and 2C19 (strong). Concentrations of lapatinib may increase due to moderate inhibition of CYP3A4. Coadministration should be approached with caution. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for lapatinib toxicity. Monitor lapatinib plasma concentrations, if available. Furthermore, lapatinib and fluconazole may cause QTc interval prolongation. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
145,Lapatinib,Flucytosine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucytosine is metabolised to 5-fluorouracil (5-FU). 5-FU is further metabolised by dihydropyrimidine dehydrogenase to an inactive metabolite. Lapatinib does not interfere with this elimination pathway. ,See Summary
146,Lapatinib,Fludrocortisone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Fludrocortisone is metabolised in the liver to inactive metabolites, possibly via CYP3A. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered fludrocortisone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with fludrocortisone. Care should be taken when orally administered fludrocortisone is coadministered with lapatinib. Monitoring for fludrocortisone toxicity is recommended. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
147,Lapatinib,Flunitrazepam,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Flunitrazepam is metabolised mainly via CYP3A4 and CYP2C19. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered flunitrazepam may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with flunitrazepam. Care should be taken when orally administered flunitrazepam is coadministered with lapatinib. Monitoring for flunitrazepam toxicity is recommended.",See Summary
148,Lapatinib,Fluoxetine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluoxetine is metabolised by CYP2D6 and CYP2C9 and to a lesser extent by CYP2C19 and CYP3A4 to form norfluoxetine. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered fluoxetine may increase and thus concentrations of norfluoxetine may decrease. Since CYP3A4 is a minor pathway, no clinically relevant effect on fluoxetine exposure is expected. Furthermore, fluoxetine is a strong inhibitor of CYP2D6 and CYP2C19. Concentrations of lapatinib may increase due to CYP2C19 inhibition. Since CYP2C19 is only a minor pathway in lapatinib metabolism, a clinically significant interaction is unlikely.",See Summary
149,Lapatinib,Fluphenazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Fluphenazine is metabolised by CYP2D6. Lapatinib does not inhibit or induce CYP2D6. However, lapatinib and fluphenazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
150,Lapatinib,Flurazepam,"
Potential Weak Interaction
","
Very Low
",Coadministration has not been studied. The metabolism of flurazepam is most likely CYP-mediated. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. The clinical relevance of this interaction is unknown. Care should be taken when flurazepam is coadministered with lapatinib. Monitoring for flurazepam toxicity is recommended.,See Summary
151,Lapatinib,Fluticasone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluticasone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Fluticasone is not orally administered and no clinically relevant interaction is expected.,See Summary
152,Lapatinib,Fluvastatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fluvastatin is mainly metabolised by CYP2C9 (75%) and to a lesser extent by CYP3A4 (20%) and CYP2C8 (5%). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib also inhibits CYP2C8 in vitro at clinically relevant concentrations. Since CYP3A4 and CYP2C8 are minor pathways, no clinically relevant interaction is expected. Furthermore, fluvastatin potentially inhibits CYP2C9. Lapatinib is not metabolised by CYP2C9.",See Summary
153,Lapatinib,Fluvoxamine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Fluvoxamine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Lapatinib does not inhibit or induce CYP2D6 or CYP1A2. Fluvoxamine is also an inhibitor of CYPs 1A2 (strong), 2C19 (strong), 3A4 (moderate), 2C9 (weak-moderate) and 2D6 (weak). Concentrations of lapatinib may increase due to inhibition of CYPs 3A4, 2C8 and 2C19. Coadministration should be approached with caution. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for lapatinib toxicity. Monitor lapatinib plasma concentrations, if available.",See Summary
154,Lapatinib,Fondaparinux,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fondaparinux does not undergo cytochrome metabolism but is predominantly renally eliminated. Lapatinib does not interfere with this elimination pathway.,See Summary
155,Lapatinib,Formoterol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Formoterol is eliminated primarily by direct glucuronidation, with O-demethylation (by CYPs 2D6, 2C19, 2C9, and 2A6) followed by further glucuronidation. As multiple CYP450 and UGT enzymes catalyse the transformation, the potential for a pharmacokinetic interaction with lapatinib is low.",See Summary
156,Lapatinib,Fosaprepitant,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Fosaprepitant is rapidly, almost completely, converted to the active metabolite aprepitant. Lapatinib does not interact with this pathway. Aprepitant is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C19. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of aprepitant may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with aprepitant. Care should be taken when orally administered aprepitant is coadministered with lapatinib. Monitoring for aprepitant toxicity is recommended. Furthermore, during treatment aprepitant is a moderate inhibitor of CYP3A4 and may increase lapatinib concentrations. Coadministration should be approached with caution. After treatment aprepitant is a weak inducer of CYP3A4, CYP2C9 and UGT. Concentrations of aprepitant may decrease due to CYP3A4 induction, but a clinically relevant effect due to CYP3A4 induction is not expected.",See Summary
157,Lapatinib,Fosphenytoin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Fosphenytoin is rapidly converted to the active metabolite phenytoin. Lapatinib does not interact with this pathway. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Lapatinib does not inhibit or induce CYP2C9 or CYP2C19. However, phenytoin is a potent inducer of CYP3A4, UGT and P-gp. Concentrations of lapatinib may decrease due to CYP3A4 and P-gp induction. In healthy volunteers, coadministration of lapatinib and carbamazepine, a potent CYP3A4 inducer, decreased systemic exposure of lapatinib by approximately 72%. A similar effect may occur after coadministration with fosphenytoin. Coadministration should be avoided. Selection of an alternative concomitant medication with no or minimal enzyme induction potential is recommended. If patients must be co-treated with fosphenytoin, pharmacokinetic studies suggest titrating the dose of lapatinib up by a factor of 3-4 based on tolerability. If fosphenytoin is discontinued the lapatinib dose should be reduced to the indicated dose. Monitor lapatinib plasma concentrations, if available.",See Summary
158,Lapatinib,Furosemide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also renally eliminated unchanged (via OATs). Lapatinib is an in vitro inhibitor of UGT1A1 at clinically relevant concentrations and may increase concentrations of furosemide. Since UGT1A1 is a minor pathway, no clinically relevant effect on furosemide exposure is expected. Furthermore, in vitro data indicate that furosemide is an inhibitor of OAT1/OAT3. Lapatinib is not transported by OATs.",See Summary
159,Lapatinib,Gabapentin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gabapentin is cleared mainly by glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
160,Lapatinib,Gemfibrozil,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gemfibrozil is metabolised by UGT2B7. Lapatinib does not inhibit or induce UGT2B7. Furthermore, gemfibrozil is an inhibitor of CYP2C8 (strong), OATP1B1 and OAT3. In vitro data indicate gemfibrozil to be a strong inhibitor of CYP2C9 but in vivo data showed no clinically relevant effect on CYP2C9. Although lapatinib is metabolised by CYP2C8 to a minor extent, a clinically significant interaction is not expected.",See Summary
161,Lapatinib,Gentamicin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gentamicin is eliminated unchanged predominantly via glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
162,Lapatinib,Gestodene,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Gestodene is metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2C19. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of gestodene may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with gestodene. Care should be taken when orally administered gestodene is coadministered with lapatinib. Monitoring for gestodene toxicity may be required. For administration routes other than oral (e.g. transdermal drugs), no clinically relevant interaction is expected.",See Summary
163,Lapatinib,Glibenclamide (Glyburide),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Glibenclamide is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered glibenclamide may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with glibenclamide. Care should be taken when orally administered glibenclamide is coadministered with lapatinib. Monitoring of blood glucose levels is recommended and adjust glibenclamide dose accordingly.",See Summary
164,Lapatinib,Gliclazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Gliclazide is metabolised mainly by CYP2C9 and to a lesser extent by CYP2C19. Lapatinib does not inhibit or induce CYP2C9 or CYP2C19.,See Summary
165,Lapatinib,Glimepiride,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glimepiride is mainly metabolised by CYP2C9. Lapatinib does not inhibit or induce CYP2C9.,See Summary
166,Lapatinib,Glipizide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Glipizide is mainly metabolised by CYP2C9. Lapatinib does not inhibit or induce CYP2C9.,See Summary
167,Lapatinib,Granisetron,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Granisetron is metabolised by CYP3A4 and is a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered granisetron may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with granisetron. If unavoidable, care should be taken when orally administered granisetron is coadministered with lapatinib. Monitoring for granisetron toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant effect on granisetron exposure is expected. However, lapatinib and granisetron may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
168,Lapatinib,Grapefruit juice,"
Do Not Coadminister
","
Very Low
","Coadministration should avoided. Grapefruit juice is a known inhibitor of CYP3A4 and may increase lapatinib concentrations. However, the magnitude of this potential interaction is difficult to predict as the effect of grapefruit juice is concentration-, dose- and preparation-dependent and varies widely across brands. Therefore, coadministration should be avoided.",See Summary
169,Lapatinib,Green tea,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. In an animal study, short-term use of green tea resulted in a decreased lapatinib AUC of 74%. Long-term administration of green tea resulted in a decreased lapatinib AUC of 22%. As the clinical relevance of this interaction is unknown, coadministration should be avoided.",See Summary
170,Lapatinib,Griseofulvin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Less than 1% of a griseofulvin dose is excreted unchanged via the kidneys. Lapatinib does not interfere with this elimination pathway. However, griseofulvin is a liver microsomal enzyme inducer and may lower plasma levels, and therefore reduce the efficacy, of concomitantly administered medicinal products metabolised by CYP3A4, such as lapatinib. Close monitoring of lapatinib efficacy is recommended.",See Summary
171,Lapatinib,Haloperidol,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Haloperidol has a complex metabolism as it undergoes glucuronidation (UGTs 2B7>1A4 and 1A9), carbonyl reduction as well as oxidative metabolism (CYP3A4 and CYP2D6). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered haloperidol may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with haloperidol. If coadministration is unavoidable, care should be taken when orally administered haloperidol is coadministered with lapatinib. Monitoring for haloperidol toxicity is recommended. For administration routes other than oral (e.g. i.m. drugs), no clinically relevant effect on haloperidol exposure is expected. Lapatinib and haloperidol may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
172,Lapatinib,Heparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Heparin is thought to be eliminated via the reticuloendothelial system. Lapatinib does not interact with this metabolic pathway.,See Summary
173,Lapatinib,Hydralazine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolised via primary oxidative metabolism and acetylation. Although in vitro studies have suggested that hydralazine is a mixed enzyme inhibitor, which may weakly inhibit CYP3A4 and CYP2D6, it is not expected that this will lead to a clinically relevant interaction with lapatinib.",See Summary
174,Lapatinib,Hydrochlorothiazide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydrochlorothiazide is not metabolised but is cleared by the kidneys via OAT1. In vitro data indicate that hydrochlorothiazide is unlikely to inhibit OAT1 in the range of clinically relevant concentrations. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Significant interactions are not expected with lapatinib.,See Summary
175,Lapatinib,Hydrocodone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Hydrocodone is metabolised by CYP2D6 to hydromorphone and by CYP3A4 to norhydrocodone, both of which have analgesic effects. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered hydrocodone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with hydrocodone. Care should be taken when orally administered hydrocodone is coadministered with lapatinib and monitoring for hydrocodone toxicity should be recommended. For administration routes other than oral (e.g. i.v. drugs), a clinically relevant interaction is not expected.",See Summary
176,Lapatinib,Hydrocortisone (oral),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Hydrocortisone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered hydrocortisone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with hydrocortisone. Care should be taken when orally administered hydrocortisone is coadministered with lapatinib. Monitoring for hydrocortisone toxicity is recommended. ",See Summary
177,Lapatinib,Hydrocortisone (topical),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with the topical use of hydrocortisone. ,See Summary
178,Lapatinib,Hydromorphone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydromorphone is eliminated via glucuronidation, mainly by UGT2B7. Lapatinib does not inhibit or induce UGT2B7. ",See Summary
179,Lapatinib,Hydroxyurea (Hydroxycarbamide),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hydroxyurea is metabolised in the liver and cleared via the lungs and kidneys. Lapatinib is unlikely to interfere with this metabolic pathway.,See Summary
180,Lapatinib,Hydroxyzine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Hydroxyzine is partly metabolised by alcohol dehydrogenase and partly by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered hydroxyzine may increase, but since CYP3A4 is a minor pathway, no clinically relevant effect on hydroxyzine exposure is expected. However, lapatinib and hydroxyzine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
181,Lapatinib,Ibandronic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ibandronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, ibandronic acid should be taken after an overnight fast (at least 6 hours) and before the first food or drink of the day. Medicinal products and supplements should be similarly avoided prior to taking ibandronic acid. Fasting should be continued for at least 30 minutes after taking ibandronic acid.",See Summary
182,Lapatinib,Ibuprofen,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ibuprofen is metabolised mainly by CYP2C9 and to a lesser extent by CYP2C8 and direct glucuronidation. Lapatinib is an in vitro inhibitor of CYP2C8, UGT2B17 and UGT1A1 at clinically relevant concentrations. However, since both CYP2C8 and glucuronidation are minor pathways, no clinically relevant effect on lapatinib exposure is expected.",See Summary
183,Lapatinib,Iloperidone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Iloperidone is metabolised by CYP3A4 and CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered iloperidone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with iloperidone. If coadministration is unavoidable, care should be taken when orally administered iloperidone is coadministered with lapatinib. Monitoring for iloperidone toxicity is recommended. Furthermore, lapatinib and iloperidone may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
184,Lapatinib,Imipenem/Cilastatin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Imipenem and cilastatin are eliminated by glomerular filtration and to a lesser extent by active tubular secretion. Lapatinib does not interfere with this elimination pathway.,See Summary
185,Lapatinib,Imipramine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Imipramine is metabolised by CYPs 3A4, 2C19 and 1A2 to desipramine. Imipramine and desipramine are both metabolised by CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered imipramine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with imipramine. Care should be taken when orally administered imipramine is coadministered with lapatinib. Monitoring for imipramine toxicity is recommended. Furthermore, lapatinib and imipramine may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
186,Lapatinib,Indapamide,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Indapamide is extensively metabolised by CYP450. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered indapamide may increase. Lapatinib is also an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. The clinical relevance of this interaction is unknown. If coadministration appears necessary, monitoring of blood pressure is recommended. Furthermore, OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Lapatinib does not interact with this pathway. Lapatinib and indapamide may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
187,Lapatinib,Insulin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
188,Lapatinib,Interferon alpha,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
189,Lapatinib,Interleukin 2 (Aldesleukin),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Interleukin-2 is mainly eliminated by glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
190,Lapatinib,Ipratropium bromide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. A small proportion of an inhaled ipratropium dose is systemically absorbed (6.9%). Metabolism is via ester hydrolysis and conjugation. Lapatinib does not interact with this metabolic pathway.,See Summary
191,Lapatinib,Irbesartan,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Irbesartan is metabolised by glucuronidation and oxidation (mainly CYP2C9). Lapatinib does not inhibit or induce CYP2C9. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring of blood pressure may be required.",See Summary
192,Lapatinib,Iron supplements,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
193,Lapatinib,Isoniazid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoniazid is acetylated in the liver to form acetylisoniazid which is then hydrolysed to isonicotinic acid and acetylhydrazine. Lapatinib does not interact with this metabolic pathway. ,See Summary
194,Lapatinib,Isosorbide dinitrate,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. In vitro studies suggest that CYP3A4 has a role in nitric oxide formation from isosorbide dinitrate. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered isosorbide dinitrate may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with isosorbide dinitrate. Care should be taken when orally administered isosorbide dinitrate is coadministered with lapatinib. Monitoring for isosorbide dinitrate toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant interaction is expected.",See Summary
195,Lapatinib,Itraconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Itraconazole is primarily metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered itraconazole may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with itraconazole. If coadministration is unavoidable, care should be taken when orally administered itraconazole is coadministered with lapatinib. Monitoring for itraconazole toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), a clinically relevant interaction is not expected. Furthermore, itraconazole is an inhibitor of CYP3A4 (strong), CYP2C9 (weak), P-gp and BCRP. Concentrations of lapatinib may increase due to inhibition of CYP3A4 and P-gp. In healthy volunteers, coadministration of lapatinib and ketoconazole, a strong CYP3A4 inhibitor, increased lapatinib exposure by approximately 3.6-fold. A similar effect may occur with itraconazole. Therefore, coadministration should be avoided. If coadministration is unavoidable, a dose reduction of 50-66% for lapatinib is recommended, based on pharmacokinetic studies. Monitor closely for lapatinib toxicity, including ECG. Monitor lapatinib plasma concentrations, if available.",See Summary
196,Lapatinib,Ivabradine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Ivabradine is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered ivabradine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with ivabradine. If coadministration is unavoidable, care should be taken when orally administered ivabradine is coadministered with lapatinib. Monitoring for ivabradine toxicity is recommended. Furthermore, lapatinib and ivabradine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
197,Lapatinib,Kanamycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Kanamycin is eliminated unchanged predominantly via glomerular filtration. Lapatinib does not interact with this elimination pathway.,See Summary
198,Lapatinib,Ketoconazole,"
Do Not Coadminister
","
Low
","Coadministration has been studied and should be avoided. Ketoconazole is a substrate of CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered ketoconazole may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45% increase. A similar effect may occur with ketoconazole. If coadministration is unavoidable, care should be taken when orally administered ketoconazole is coadministered with lapatinib. Monitoring for ketoconazole toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), a clinically relevant effect on ketoconazole exposure is not expected. Furthermore, ketoconazole is an inhibitor of CYP3A4 (strong) and P-gp, and may increase concentrations of lapatinib. In healthy volunteers, coadministration of lapatinib and ketoconazole increased lapatinib exposure by approximately 3.6-fold. Coadministration should be avoided. If coadministration is unavoidable, a dose reduction of 50-65% for lapatinib is recommended, based on pharmacokinetic studies. Monitor closely for lapatinib toxicity, including ECG. Monitor lapatinib plasma concentrations, if available.",See Summary
199,Lapatinib,Labetalol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Labetalol is mainly glucuronidated (via UGT1A1 and UGT2B7). Lapatinib is an in vitro inhibitor of UGT1A1 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for labetalol toxicity may be required.",See Summary
200,Lapatinib,Lacidipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Lacidipine is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered lacidipine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with lacidipine. Care should be taken when orally administered lacidipine is coadministered with lapatinib. If coadministration with orally administered lacidipine appears necessary, monitoring of blood pressure is recommended.",See Summary
201,Lapatinib,Lactulose,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lactulose to lactic acid occurs via gastro-intestinal microbial flora only. Lapatinib is unlikely to interfere with this metabolic pathway.,See Summary
202,Lapatinib,Lansoprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Lansoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of lansoprazole may increase. Since CYP3A4 is a minor pathway, no clinically relevant effect due on lansoprazole exposure is expected. However, the solubility of lapatinib is pH-dependent. Pre-treatment with a proton pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 26%. A similar effect may occur with lansoprazole. A decrease in exposure may lead to a decrease in lapatinib efficacy. If coadministration is unavoidable, monitor lapatinib efficacy and lapatinib plasma concentrations, if available.",See Summary
203,Lapatinib,Lercanidipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Lercanidipine is mainly metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered lercanidipine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with lercanidipine. Care should be taken when orally administered lercanidipine is coadministered with lapatinib. If coadministration with orally administered lercanidipine appears necessary, monitoring of blood pressure is recommended.",See Summary
204,Lapatinib,Levocetirizine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Less than 14% of a dose of levocetirizine is metabolised. Levocetirizine is mainly eliminated unchanged in the urine through both glomerular filtration and tubular secretion. Lapatinib is unlikely to interfere with this elimination pathway.,See Summary
205,Lapatinib,Levofloxacin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Levofloxacin is renally eliminated mainly by glomerular filtration and active secretion (possibly OCT2). Lapatinib does not interfere with this elimination pathway. However, lapatinib and levofloxacin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
206,Lapatinib,Levomepromazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Levomepromazine is metabolised by CYP2D6. Lapatinib does not inhibit or induce CYP2D6. However, lapatinib and levomepromazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
207,Lapatinib,Levonorgestrel,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Levonorgestrel is metabolised by CYP3A4 and is glucuronidated to a minor extent. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. Since glucuronidation is a minor pathway, a clinically relevant effect due to UGT inhibition is unlikely. Lapatinib is also a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of levonorgestrel may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with levonorgestrel. Care should be taken when orally administered levonorgestrel is coadministered with lapatinib. Monitoring for levonorgestrel toxicity may be required. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
208,Lapatinib,Levonorgestrel (Emergency Contraception),"
Potential Interaction
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. However, the use of levonorgestrel as emergency contraception is a relative contraindication due to the risk of a pregnancy while having a hormone-sensitive tumour. Therefore, the following information is applicable: Coadministration has not been studied. Levonorgestrel is metabolised by CYP3A4 and is glucuronidated to a minor extent. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of levonorgestrel may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with levonorgestrel. Care should be taken when orally administered levonorgestrel is coadministered with lapatinib. Monitoring for levonorgestrel toxicity may be required. Furthermore, lapatinib is in vitro inhibitor of UGT1A1 and UGT2B7 at clinical relevant concentrations. Since glucuronidation is a minor pathway, a clinically relevant interaction is unlikely.",See Summary
209,Lapatinib,Levothyroxine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Levothyroxine is metabolised by deiodination (by enzymes of deiodinase family) and glucuronidation. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring of TSH and T4 may be required.",See Summary
210,Lapatinib,Lidocaine (Lignocaine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP1A2 is the predominant enzyme involved in lidocaine metabolism in the range of therapeutic concentrations with a minor contribution from CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered lidocaine may increase but since CYP3A4 is only a minor pathway, no clinically relevant interaction is expected.",See Summary
211,Lapatinib,Linagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Linagliptin is mainly eliminated as parent compound in faeces with metabolism by CYP3A4 representing a minor metabolic pathway. Linagliptin is also a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway, no clinically relevant effect due to CYP3A4 inhibition is expected. However, lapatinib is also an inhibitor of P-gp. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with linagliptin. Monitoring of blood glucose levels is recommended and adjust linagliptin dose accordingly. Furthermore, linagliptin is an inhibitor of CYP3A4 and may increase concentrations of lapatinib. The clinical relevance of this interaction is unknown. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered.",See Summary
212,Lapatinib,Linezolid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linezolid undergoes non CYP mediated metabolism. Lapatinib is unlikely to interfere with this metabolic pathway.,See Summary
213,Lapatinib,Liraglutide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Liraglutide is degraded by endogenous endopeptidases. Lapatinib is unlikely to interfere with this metabolic pathway.,See Summary
214,Lapatinib,Lisinopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is renally eliminated unchanged via glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
215,Lapatinib,Lithium,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Lithium is mainly eliminated unchanged through the kidneys. Lithium is freely filtered at a rate that is dependent upon the glomerular filtration rate therefore no pharmacokinetic interaction is expected. However, lapatinib and lithium may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
216,Lapatinib,Live vaccines,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied. In patients, who are receiving cytotoxics or other immunosuppressant drugs, use of live vaccines for immunisation is contraindicated. However, lapatinib is not an immunosuppressant, immunomodulatory or bone marrow toxic drug. Therefore, no interaction is expected with live vaccines.",See Summary
217,Lapatinib,Loperamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Loperamide is mainly metabolised by CYP3A4 and CYP2C8. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. Concentrations of loperamide may increase due to inhibition of CYP3A4 and CYP2C8, but the clinical relevance is unknown. Furthermore, loperamide is a substrate of P-gp. Lapatinib is an inhibitor of P-gp. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with lapatinib. However, since loperamide has a very broad therapeutic index, a clinically relevant effect on loperamide exposure is not expected.",See Summary
218,Lapatinib,Loratadine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Loratadine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered loratadine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with loratadine. Care should be taken when orally administered loratadine is coadministered with lapatinib. Monitoring for loratadine toxicity is recommended.",See Summary
219,Lapatinib,Lorazepam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lorazepam is eliminated by non-CYP-mediated pathways and no effect on plasma concentrations is expected when coadministered with lapatinib. ,See Summary
220,Lapatinib,Lormetazepam,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Lormetazepam is mainly glucuronidated. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for lormetazepam toxicity may be required.",See Summary
221,Lapatinib,Losartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Losartan is converted to its active metabolite mainly by CYP2C9 in the range of clinical concentrations. Lapatinib does not inhibit or induce CYP2C9. ,See Summary
222,Lapatinib,Lovastatin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Lovastatin is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered lovastatin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with lovastatin. If coadministration is unavoidable, monitor for lovastatin toxicity.",See Summary
223,Lapatinib,Macitentan,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Macitentan is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C19, 2C9 and 2C8. Lapatinib is an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. Since CYP2C8 is a minor pathway, a clinically relevant effect due to CYP2C8 inhibition is not expected. Lapatinib is also a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered macitentan may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with macitentan. Care should be taken when orally administered macitentan is coadministered with lapatinib. If coadministration with orally administered macitentan appears necessary, monitoring of blood pressure is recommended.",See Summary
224,Lapatinib,Magnesium,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Magnesium is eliminated in the kidney, mainly by glomerular filtration. Lapatinib does not interfere with this elimination pathway.",See Summary
225,Lapatinib,Maprotiline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Maprotiline is mainly metabolised by CYP2D6. Lapatinib does not inhibit or induce CYP2D6. ,See Summary
226,Lapatinib,Medroxyprogesterone (depot),"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Medroxyprogesterone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since medroxyprogesterone IM depot injection is not orally administered, no clinically relevant interaction is expected.",See Summary
227,Lapatinib,Medroxyprogesterone (non-depot),"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Medroxyprogesterone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of medroxyprogesterone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with medroxyprogesterone. Care should be taken when orally administered medroxyprogesterone is coadministered with lapatinib. Monitoring for medroxyprogesterone toxicity may be required. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
228,Lapatinib,Mefenamic acid,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mefenamic acid is metabolised by CYP2C9 and glucuronidated by UGT2B7 and UGT1A9. Lapatinib does not inhibit or induce CYP2C9, UGT2B7 or UGT1A9. ",See Summary
229,Lapatinib,Megestrol acetate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Megestrol acetate is mainly eliminated in the urine. Lapatinib does not interfere with this elimination pathway.,See Summary
230,Lapatinib,Meropenem,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Meropenem is primarily eliminated by the kidney with in vitro data suggesting it is a substrate of OAT3>OAT1. Lapatinib does not interfere with this elimination pathway.,See Summary
231,Lapatinib,Mesalazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mesalazine is metabolised to N-acetyl-mesalazine by N-acetyltransferase. Lapatinib does not interfere with this pathway. ,See Summary
232,Lapatinib,Metamizole,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Metamizole is metabolised by hydrolysis to the active metabolite MAA in the gastrointestinal tract. Metamizole is metabolised in serum and excreted via urine (90%) and faeces (10%). Lapatinib does not interact with this pathway. However, metamizole is an inducer of CYP3A4 and may decrease lapatinib concentrations. The clinical relevance of this interaction is unknown. No a priori dose adjustment for lapatinib is recommended. Closely monitor for decreased lapatinib efficacy. Monitor lapatinib plasma concentrations, if available.",See Summary
233,Lapatinib,Metformin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metformin is mainly eliminated unchanged in the urine and is a substrate of OCT1/2/3, MATE1 and MATE2K. Lapatinib does not interact with this elimination pathway.",See Summary
234,Lapatinib,Methadone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Methadone is demethylated by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered methadone may increase. Care should be taken when orally administered methadone is coadministered with lapatinib and monitoring for methadone toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant effect on methadone exposure is expected. However, lapatinib and methadone may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
235,Lapatinib,Methyldopa,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methyldopa is excreted in urine largely by glomerular filtration, primarily unchanged and as the mono-O-sulfate conjugate. It is unlikely to affect the disposition of lapatinib, or to be altered by coadministration with lapatinib.",See Summary
236,Lapatinib,Methylphenidate,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylphenidate is not metabolised by cytochrome P450 to a clinically relevant extent and does not inhibit or induce cytochrome P450s. ,See Summary
237,Lapatinib,Methylprednisolone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Methylprednisolone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since methylprednisolone is not orally administered, a clinically relevant interaction is unlikely.",See Summary
238,Lapatinib,Metoclopramide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoclopramide is partially metabolised by the CYP450 system (mainly CYP2D6). Lapatinib does not inhibit or induce CYP2D6. ,See Summary
239,Lapatinib,Metolazone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metolazone is largely excreted unchanged in the urine. OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Lapatinib is unlikely to interfere with this elimination pathway.,See Summary
240,Lapatinib,Metoprolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolised by CYP2D6. Lapatinib does not inhibit or induce CYP2D6.,See Summary
241,Lapatinib,Metronidazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Metronidazole is eliminated via glomerular filtration. Lapatinib is unlikely to interfere with this elimination pathway. However, elevated plasma concentrations have been reported for some CYP3A substrates (e.g. tacrolimus, cyclosporine) with metronidazole, but metronidazole did not increase concentrations of several CYP3A probe drugs (e.g. midazolam, alprazolam). Since the mechanism of the interaction with CYP3A has not yet been identified, an interaction with lapatinib cannot be excluded and monitoring for lapatinib toxicity may be required.",See Summary
242,Lapatinib,Mexiletine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mexiletine is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2. Lapatinib does not inhibit or induce CYP2D6 or CYP1A2. ,See Summary
243,Lapatinib,Mianserin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mianserin is metabolised by CYP2D6 and CYP1A2, and to a lesser extent by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway, no clinically relevant interaction is expected.",See Summary
244,Lapatinib,Miconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Miconazole is extensively metabolised by the liver. Lapatinib is unlikely to interfere with this metabolic pathway. However, miconazole is an inhibitor of CYP2C9 (moderate) and CYP3A4 (strong). Concentrations of lapatinib may increase due to inhibition of CYP3A4. In healthy volunteers, coadministration of lapatinib and ketoconazole, a strong CYP3A4 inhibitor, increased lapatinib exposure by approximately 3.6-fold. A similar effect may occur with miconazole. Coadministration should be avoided. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, a dose reduction of 50-66% for lapatinib is recommended, based on pharmacokinetic studies. Monitor closely for lapatinib toxicity, including ECG. Monitor lapatinib plasma concentrations, if available.",See Summary
245,Lapatinib,Midazolam (oral),"
Potential Weak Interaction
","
Moderate
",Midazolam is metabolised by CYP3A4. Coadministration of lapatinib with orally administered midazolam increased midazolam AUC by 45%. Care should be taken when orally administered midazolam is coadministered with lapatinib. Monitoring for midazolam toxicity is recommended.,See Summary
246,Lapatinib,Midazolam (parenteral),"
No Interaction Expected
","
Moderate
",Midazolam is metabolised by CYP3A4. Coadministration of lapatinib with i.v. midazolam resulted in no clinically meaningful increase in midazolam AUC.,See Summary
247,Lapatinib,Milnacipran,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Milnacipran is mainly eliminated unchanged (50%), and as glucuronides (30%) and oxidative metabolites (20%). Lapatinib is unlikely to interfere with this pathway.",See Summary
248,Lapatinib,Mirtazapine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Mirtazapine is metabolised to 8-hydroxymirtazapine by CYP2D6 and CYP1A2, and to N-desmethylmirtazapine mainly by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered mirtazapine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with mirtazapine. Care should be taken when orally administered mirtazapine is coadministered with lapatinib. Monitoring for mirtazapine toxicity is recommended.",See Summary
249,Lapatinib,Mometasone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mometasone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. However, since mometasone is not administered orally, a clinically relevant interaction is unlikely.",See Summary
250,Lapatinib,Montelukast,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Montelukast is mainly metabolised by CYP2C8 and to a lesser extent by CYP3A4 and CYP2C9. Lapatinib is an in vitro inhibitor of CYP2C8 at clinically relevant concentrations, but the clinical relevance of CYP2C8 inhibition is unknown. Furthermore, lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Montelukast concentrations may increase and caution should be exercised. A dose reduction of montelukast should be considered. Monitor closely for montelukast toxicity.",See Summary
251,Lapatinib,Morphine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Morphine is mainly glucuronidated to morphine-3-glucuronide (UGT2B7>UGT1A1) and to a lesser extent, to the pharmacologically active morphine-6-glucuronide (UGT2B7>UGT1A1). Morphine is also a substrate of P-gp. Lapatinib is an in vitro inhibitor of UGT1A1 at clinical relevant concentrations. Since UGT1A1 is a minor pathway, a clinically relevant effect due to UGT1A1 inhibition is not expected. However, lapatinib is also an inhibitor of P-gp. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with morphine. Monitoring for morphine toxicity is recommended.",See Summary
252,Lapatinib,Moxifloxacin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Moxifloxacin is predominantly glucuronidated by UGT1A1. Lapatinib is an in vitro inhibitor of UGT1A1 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for moxifloxacin toxicity may be required. Furthermore, lapatinib and moxifloxacin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
253,Lapatinib,Mycophenolate,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mycophenolate is mainly glucuronidated by UGT1A9 and UGT2B7. Lapatinib does not inhibit or induce UGT1A9 or UGT2B7. In addition, inhibition of OAT1/OAT3 renal transporters by mycophenolic acid (active metabolite) is unlikely to interfere with lapatinib elimination.",See Summary
254,Lapatinib,Nadroparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nadroparin is renally excreted by a nonsaturable mechanism. Lapatinib does not interfere with this elimination pathway.,See Summary
255,Lapatinib,Nandrolone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nandrolone is metabolised in the liver by alpha-reductase. Lapatinib does not interact with this metabolic pathway.,See Summary
256,Lapatinib,Naproxen,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naproxen is mainly glucuronidated by UGT2B7 (major) and demethylated to desmethylnaproxen by CYP2C9 (major) and CYP1A2. Lapatinib does not inhibit or induce UGT2B7, CYP2C9 or CYP1A2.",See Summary
257,Lapatinib,Nateglinide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nateglinide is mainly metabolised by CYP2C9 (70%) and to a lesser extent by CYP3A4 (30%). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered nateglinide may increase. However, since CYP3A4 is a minor pathway, no clinically significant effect on nateglinide exposure is expected.",See Summary
258,Lapatinib,Nebivolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nebivolol metabolism involves CYP2D6. Lapatinib does not inhibit or induce CYP2D6.,See Summary
259,Lapatinib,Nefazodone,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Nefazodone is metabolised mainly by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered nefazodone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with nefazodone. Care should be taken when orally administered nefazodone is coadministered with lapatinib. Monitoring for nefazodone toxicity is recommended. Furthermore, nefazodone is a strong inhibitor of CYP3A4 and may increase concentrations of lapatinib. In healthy volunteers, coadministration of lapatinib and ketoconazole, a strong CYP3A4 inhibitor, increased lapatinib exposure by approximately 3.6-fold. A similar effect may occur with nefazodone. Coadministration should be avoided. If coadministration is unavoidable, a dose reduction of 55-60% for lapatinib is recommended, based on pharmacokinetic studies. Monitor closely for lapatinib toxicity, including ECG. Monitor lapatinib plasma concentrations, if available.",See Summary
260,Lapatinib,Nicardipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Nicardipine is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP2C8. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since nicardipine is not orally administered, a clinically relevant effect on nicardipine exposure is not expected. However, nicardipine is a weak inhibitor of CYP3A4 and may increase lapatinib concentrations. As the clinical relevance of this interaction is unknown, selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered.",See Summary
261,Lapatinib,Nicotinamide (Niacinamide),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nicotinamide is converted to N-methylnicotinamide by nicotinamide methyltransferase which in turn is metabolised by xanthine oxidase and aldehyde oxidase. Lapatinib does not interact with this metabolic pathway. In addition, nicotinic acid and its metabolites do not inhibit CYP-mediated reactions in vitro and therefore are unlikely to impact lapatinib exposure.",See Summary
262,Lapatinib,Nifedipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Nifedipine is metabolised mainly by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of nifedipine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with orally administered nifedipine. Care should be taken when orally administered nifedipine is coadministered with lapatinib. Monitoring for nifedipine toxicity is recommended.",See Summary
263,Lapatinib,Nimesulide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nimesulide is extensively metabolised in the liver following multiple pathways including CYP2C9. Lapatinib does not inhibit or induce CYP2C9.,See Summary
264,Lapatinib,Nisoldipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Nisoldipine is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of nisoldipine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with orally administered nifedipine. Care should be taken when orally administered nisoldipine is coadministered with lapatinib. Monitoring for nisoldipine toxicity is recommended.",See Summary
265,Lapatinib,Nitrendipine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Nitrendipine is extensively metabolised mainly by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of nitrendipine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with nitrendipine. Care should be taken when orally administered nitrendipine is coadministered with lapatinib. Monitoring for nitrendipine toxicity is recommended.",See Summary
266,Lapatinib,Nitrofurantoin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Nitrofurantoin is partly metabolised in the liver via glucuronidation and N-acetylation, and partly eliminated in the urine as unchanged drug (30-40%). Lapatinib does not interact with this metabolic pathway.",See Summary
267,Lapatinib,Norelgestromin,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norelgestromin is metabolised to norgestrel (possibly by CYP3A4). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since norelgestromin is not orally administered, a clinically relevant interaction is not expected.",See Summary
268,Lapatinib,Norethisterone (Norethindrone),"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Norethisterone is extensively biotransformed, first by reduction and then by sulfate and glucuronide conjugation. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for norethisterone toxicity may be required.",See Summary
269,Lapatinib,Norgestimate,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Norgestimate is rapidly deacetylated to the active metabolite which is further metabolised via CYP450. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib also inhibits CYP2C8 in vitro at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for norgestimate toxicity may be required.",See Summary
270,Lapatinib,Norgestrel,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Norgestrel is a racemic mixture with levonorgestrel being biologically active. Levonorgestrel is metabolised by CYP3A4 and is glucuronidated to a minor extent. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. Since glucuronidation is a minor pathway, a clinically relevant effect due to glucuronidation is unlikely. Lapatinib is also a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of norgestrel may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with levonorgestrel. Care should be taken when orally administered levonorgestrel is coadministered with lapatinib. Monitoring for levonorgestrel toxicity may be required. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
271,Lapatinib,Nortriptyline,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Nortriptyline is metabolised mainly by CYP2D6. Lapatinib does not inhibit or induce CYP2D6. However, lapatinib and nortriptyline may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
272,Lapatinib,Nystatin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosage forms is not significant, therefore no drug interactions are expected. ",See Summary
273,Lapatinib,Ofloxacin,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Ofloxacin is renally eliminated unchanged by glomerular filtration and active tubular secretion via both cationic and anionic transport systems. Lapatinib is unlikely to interfere with this elimination pathway. However, lapatinib and ofloxacin may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
274,Lapatinib,Olanzapine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olanzapine is metabolised mainly by CYP1A2 (major) and CYP2D6, but also by glucuronidation (UGT1A4). Lapatinib does not inhibit or induce CYP1A2, CYP2D6 or UGT1A4. ",See Summary
275,Lapatinib,Olmesartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Olmesartan medoxomil is de-esterified to the active metabolite olmesartan which is eliminated in the faeces and urine. Lapatinib does not interfere with this elimination pathway.,See Summary
276,Lapatinib,Omeprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Omeprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway, no clinically relevant effect on omeprazole exposure is expected. Furthermore, omeprazole induces CYP1A2 and inhibits CYP2C19. Since CYP2C19 is a minor pathway in lapatinib metabolism, no clinically significant effect due to CYP2C19 inhibition is expected. However, the solubility of lapatinib is pH-dependent. Pre-treatment with a proton pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 26%. A similar effect may occur with omeprazole. A decrease in exposure may lead to a decrease in lapatinib efficacy. If coadministration is unavoidable, monitor lapatinib efficacy and lapatinib plasma concentrations, if available.",See Summary
277,Lapatinib,Ondansetron,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Ondansetron is metabolised mainly by CYP1A2 and CYP3A4, and to a lesser extent by CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of ondansetron may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with ondansetron. Ondansetron is also a substrate of P-gp. Lapatinib is an inhibitor of P-gp. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with ondansetron. Monitoring for ondansetron toxicity is recommended. Furthermore, lapatinib and ondansetron may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
278,Lapatinib,Oxazepam,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Oxazepam is mainly glucuronidated. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations, and may increase concentrations of oxazepam. As the clinical relevance of this interaction is unknown, monitoring for oxazepam toxicity may be required.",See Summary
279,Lapatinib,Oxcarbazepine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Oxcarbazepine is extensively metabolised to the active metabolite monohydroxyderivate (MHD) through cystolic enzymes. Lapatinib does not interact with this metabolic pathway. Both oxcarbazepine and MHD are inducers of CYP3A4 (moderate) and CYP3A5, and are inhibitors of CYP2C19. Concentrations of lapatinib may decrease due to CYP3A4 induction. The clinical relevance of this interaction is unknown. No a priori dose adjustment for lapatinib is recommended. Monitor closely for decreased lapatinib efficacy. Monitor lapatinib plasma concentrations, if available.",See Summary
280,Lapatinib,Oxprenolol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Oxprenolol is largely metabolised via glucuronidation. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations, and may increase concentrations of oxprenolol. As the clinical relevance of this interaction is unknown, monitoring of blood pressure may be required.",See Summary
281,Lapatinib,Oxycodone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Oxycodone is metabolised principally to noroxycodone via CYP3A and oxymorphone via CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered oxycodone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with oxycodone. Care should be taken when orally administered oxycodone is coadministered with lapatinib. Monitoring for oxycodone toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), a clinically relevant interaction is not expected.",See Summary
282,Lapatinib,Paliperidone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Paliperidone is primarily renally eliminated (possibly via OCT) with minimal metabolism occurring via CYP2D6 and CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered paliperidone may increase. However, since CYP3A4 is a minor pathway, no clinically significant effect on paliperidone exposure is expected.",See Summary
283,Lapatinib,Palonosetron,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Palonosetron is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6 and CYP1A2. Lapatinib does not inhibit or induce CYP2D6. However, lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered palonosetron may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with palonosetron. Furthermore, palonosetron is a substrate of P-gp. Lapatinib is an inhibitor of P-gp. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with palonosetron. Monitoring for palonosetron toxicity is recommended.",See Summary
284,Lapatinib,Pamidronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pamidronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Lapatinib does not interfere with this elimination pathway.,See Summary
285,Lapatinib,Pantoprazole,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Pantoprazole is mainly metabolised by CYP2C19 and to a lesser extent by CYPs 3A4, 2D6 and 2C9. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of pantoprazole may increase. Since CYP3A4 is a minor pathway, no clinically relevant effect on pantoprazole exposure is expected. However, the solubility of lapatinib is pH-dependent. Pre-treatment with a proton pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 26%. A similar effect may occur with pantoprazole. A decrease in exposure may lead to a decrease in lapatinib efficacy. If coadministration is unavoidable, monitor lapatinib efficacy and lapatinib plasma concentrations, if available.",See Summary
286,Lapatinib,Para-aminosalicylic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Para-aminosalicylic acid and its acetylated metabolite are mainly excreted in the urine by glomerular filtration and tubular secretion. Lapatinib does not interfere with this elimination pathway.,See Summary
287,Lapatinib,Paracetamol (Acetaminophen),"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Paracetamol is mainly metabolised by glucuronidation (via UGTs 1A9 (major), 1A6, 1A1, 2B15), sulfation and to a lesser extent by oxidation (CYPs 2E1 (major), 1A2, 3A4 and 2D6). Lapatinib is an in vitro inhibitor of UGT1A1 at clinically relevant concentrations. In vitro data showed an IC50 for glucuronidation of paracetamol of >100 µM, while lapatinib Cmax reaches concentrations up to 4.2 µM. Therefore, UGT1A1 inhibition is unlikely to lead to a clinically relevant effect on paracetamol exposure. Lapatinib is also a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered paracetamol may increase, but since paracetamol already has high bioavailability a clinically relevant effect on paracetamol exposure is not expected. However, animal studies have shown that paracetamol does have an effect on lapatinib exposure. The clinical relevance of this interaction is unknown. Coadministration should be approached with caution. Monitor for lapatinib toxicity and plasma concentrations, if available.",See Summary
288,Lapatinib,Paroxetine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Paroxetine is mainly metabolised by CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered paroxetine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with paroxetine. Care should be taken when orally administered paroxetine is coadministered with lapatinib. Monitoring for paroxetine toxicity is recommended. Paroxetine is also an inhibitor of CYP2D6 (strong) and CYP2C9. Lapatinib is not a substrate of these CYPs. ",See Summary
289,Lapatinib,Peginterferon alfa-2a,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
290,Lapatinib,Penicillins,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Penicillins are mainly eliminated in the urine (20% by glomerular filtration and 80% by tubular secretion via OAT). Lapatinib does not interfere with this elimination pathway.,See Summary
291,Lapatinib,Perazine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Perazine is mainly metabolised by CYPs 1A2, 3A4 and 2C19, and to a lesser extent by CYPs 2C9, 2D6 and 2E1, with oxidation via FMO3. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered perazine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with perazine. Care should be taken when orally administered perazine is coadministered with lapatinib. Monitoring for perazine toxicity is recommended. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
292,Lapatinib,Periciazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of periciazine has not been well characterized but is likely to involve CYP2D6. Lapatinib does not inhibit or induce CYP2D6.,See Summary
293,Lapatinib,Perindopril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Perindopril is hydrolysed to the active metabolite perindoprilat and is metabolised to other inactive metabolites. Elimination occurs predominantly via the urine. Lapatinib does not interfere with this metabolic pathway.,See Summary
294,Lapatinib,Perphenazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Perphenazine is metabolised by CYP2D6. Lapatinib does not inhibit or induce CYP2D6. However, lapatinib and perphenazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
295,Lapatinib,Pethidine (Meperidine),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolised mainly by CYP2B6 and to a lesser extent by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway in pethidine metabolism, a clinically relevant interaction is unlikely.",See Summary
296,Lapatinib,Phenelzine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Phenelzine is primarily metabolised by oxidation via monoamine oxidase and to a lesser extent by acetylation. Lapatinib is unlikely to interfere with this metabolic pathway.,See Summary
297,Lapatinib,Phenobarbital (Phenobarbitone),"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Phenobarbital is metabolised by CYP2C19 and CYP2C9 (major pathway) and to a lesser extent by CYP2E1. Lapatinib does not inhibit or induce CYPs 2C19, 2C9 or 2E1. However, phenobarbital is a strong inducer of CYPs 3A4, 2C9, 2C8 and UGTs. Concentrations of lapatinib may decrease due to CYP3A4 induction. In healthy volunteers, coadministration of lapatinib and carbamazepine, a strong CYP3A4 inducer, decreased systemic exposure of lapatinib by approximately 72%. A similar effect may occur after coadministration with phenobarbital. Coadministration should be avoided. Selection of an alternative concomitant medication with no or minimal enzyme induction potential is recommended. If patients must be co-treated with phenobarbital, pharmacokinetic studies suggest titrating the dose of lapatinib up by a factor of 3-4 based on tolerability. If phenobarbital is discontinued the lapatinib dose should be reduced to the indicated dose. Monitor lapatinib plasma concentrations, if available.",See Summary
298,Lapatinib,Phenprocoumon,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Phenprocoumon is metabolised by CYP2C9 and CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered phenprocoumon may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with phenprocoumon. Care should be taken when orally administered phenprocoumon is coadministered with lapatinib. Monitoring for phenprocoumon toxicity and INR/PT is recommended.",See Summary
299,Lapatinib,Phenytoin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Phenytoin is mainly metabolised by CYP2C9 and to a lesser extent by CYP2C19. Lapatinib does not inhibit or induce CYP2C9 or CYP2C19. However, phenytoin is a potent inducer of CYP3A4, UGT and P-gp. Concentrations of lapatinib may decrease due to CYP3A4 and P-gp induction. In healthy volunteers, coadministration of lapatinib and carbamazepine, a strong CYP3A4 inducer, decreased systemic exposure of lapatinib by approximately 72%. A similar effect may occur after coadministration with phenytoin. Coadministration should be avoided. Selection of an alternative concomitant medication with no or minimal enzyme induction potential is recommended. If patients must be co-treated with phenytoin, pharmacokinetic studies suggest titrating the dose of lapatinib up by a factor of 3-4 based on tolerability. If phenytoin is discontinued the lapatinib dose should be reduced to the indicated dose. Monitor lapatinib plasma concentrations, if available.",See Summary
300,Lapatinib,Phytomenadione (Vitamin K),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. An in vitro study found that the only CYP450 enzyme involved in phytomenadione metabolism was CYP4F2. Lapatinib does not inhibit or induce CYP4F2.,See Summary
301,Lapatinib,Pimozide,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but is contraindicated. Pimozide is mainly metabolised by CYP3A4, CYP2D6 and to a lesser extent by CYP1A2. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered pimozide may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with pimozide. Furthermore, the product labels for pimozide contraindicate its use in the presence of other drugs that prolong the QT interval, such as lapatinib.  ",See Summary
302,Lapatinib,Pindolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is partly metabolised to hydroxymetabolites (possibly via CYP2D6) and partly eliminated unchanged in the urine. Lapatinib is unlikely to interfere with this metabolic pathway.,See Summary
303,Lapatinib,Pioglitazone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Pioglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYPs 3A4, 1A2 and 2C9. Lapatinib is an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. The clinical relevance of this interaction is unknown. Furthermore, lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of pioglitazone may increase. Monitoring of blood glucose levels is recommended and adjust pioglitazone dose accordingly.",See Summary
304,Lapatinib,Pipotiazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Lapatinib does not inhibit or induce CYP2D6. However, lapatinib and pipotiazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
305,Lapatinib,Piroxicam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Piroxicam is primarily metabolised by CYP2C9. Lapatinib does not inhibit or induce CYP2C9.,See Summary
306,Lapatinib,Pitavastatin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Pitavastatin is metabolised by UGTs 1A3 and 2B7 with minimal metabolism by CYPs 2C9 and 2C8. Pitavastatin is also a substrate of OATP1B1. Lapatinib inhibits CYP2C8 and OATP1B1 in vitro at clinically relevant concentrations and may increase concentrations of pitavastatin. A clinically relevant effect due to CYP2C8 inhibtion is unlikely. However, the clinical relevance of OATP1B1 inhibition is unknown. Monitoring for pitavastatin toxicity may be required.",See Summary
307,Lapatinib,Posaconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Posaconazole is primarily metabolised by UGTs and is a substrate of P-gp. Lapatinib is an inhibitor of P-gp and an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with posaconazole. If coadministration is unavoidable, caution should be exercised and a dose reduction of posaconazole should be considered. Monitor for posaconazole toxicity. Furthermore, posaconazole is a strong inhibitor of CYP3A4 and may increase lapatinib concentrations. In healthy volunteers, coadministration of lapatinib and ketoconazole, a strong CYP3A4 inhibitor, increased lapatinib exposure by approximately 3.6-fold. A similar effect may occur with posaconazole. Coadministration should be avoided. If coadministration is unavoidable, a dose reduction of 50-65% for lapatinib is recommended, based on pharmacokinetic studies. Monitor closely for lapatinib toxicity, including ECG. Monitor lapatinib plasma concentrations, if available.",See Summary
308,Lapatinib,Potassium,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on limited data available an interaction appears unlikely. Potassium is renally eliminated. Lapatinib does not interfere with this elimination pathway.,See Summary
309,Lapatinib,Prasugrel,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Prasugrel is a prodrug and is converted to its active metabolite mainly by CYP3A4 and CYP2B6, and to a lesser extent by CYP2C9 and CYP2C19. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered prasugrel may increase and thus concentrations of the active metabolite may decrease. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with prasugrel. Care should be taken when orally administered prasugrel is coadministered with lapatinib. Monitoring for prasugrel toxicity and efficacy is recommended. A thrombocyte aggregation function test is also recommended.",See Summary
310,Lapatinib,Pravastatin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Pravastatin is minimally metabolised (via CYP3A4) and is a substrate of OATP1B1. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an in vitro inhibitor of OATP1B1. Concentrations of pravastatin may increase. A clinically relevant effect due to CYP3A4 inhibition is unlikely. However, the clinical relevance of OATP1B1 inhibition is unknown. Monitoring for pravastatin toxicity may be required.",See Summary
311,Lapatinib,Prazosin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prazosin is extensively metabolised, primarily by demethylation and conjugation. Lapatinib does not interact with this metabolic pathway.",See Summary
312,Lapatinib,Prednisolone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Prednisolone undergoes hepatic metabolism via CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered prednisolone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with prednisolone. Care should be taken when orally administered prednisolone is coadministered with lapatinib. Monitoring for prednisolone toxicity is recommended. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
313,Lapatinib,Prednisone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Lapatinib does not interact with this metabolic pathway. Prednisolone undergoes hepatic metabolism via CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Prednisone is converted to prednisolone in the liver. Therefore, no clinically relevant effect on prednisolone exposure is expected. ",See Summary
314,Lapatinib,Pregabalin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pregabalin is cleared mainly by glomerular filtration (90% as unchanged drug). Lapatinib does not interfere with this elimination pathway.,See Summary
315,Lapatinib,Prochlorperazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Prochlorperazine is metabolised by CYP2D6 and CYP2C19. Lapatinib does not inhibit or induce CYP2D6 or CYP2C19. However, lapatinib and prochlorperazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
316,Lapatinib,Promethazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Promethazine is metabolised by CYP2D6. Lapatinib does not inhibit or induce CYP2D6. However, lapatinib and promethazine may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
317,Lapatinib,Propafenone,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propafenone is metabolised mainly by CYP2D6 and to a lesser extent by CYP1A2 and CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered propafenone may increase but since CYP3A4 is a minor pathway, no clinically relevant interaction is expected.",See Summary
318,Lapatinib,Propranolol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Propranolol is metabolised by 3 routes (aromatic hydroxylation by CYP2D6, N-dealkylation followed by side chain hydroxylation via CYPs 1A2, 2C19, 2D6, and direct glucuronidation). Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring of blood pressure may be required.",See Summary
319,Lapatinib,Prucalopride,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride is minimally metabolised and mainly renally eliminated, partly by active secretion by renal transporters. No clinically relevant interactions were observed when prucalopride was coadministered with inhibitors of renal P-gp, OAT and OCT transporters.",See Summary
320,Lapatinib,Pyrazinamide,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolised by xanthine oxidase. Lapatinib does not interact with this metabolic pathway. ,See Summary
321,Lapatinib,Pyridoxine (Vitamin B6),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
322,Lapatinib,Quetiapine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Quetiapine is primarily metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered quetiapine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with quetiapine. Care should be taken when orally administered quetiapine is coadministered with lapatinib. Monitoring for quetiapine toxicity is recommended.",See Summary
323,Lapatinib,Quinapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Quinapril is de-esterified to the active metabolite quinaprilat which is eliminated primarily via OAT3. Lapatinib does not inhibit or induce OAT3.,See Summary
324,Lapatinib,Quinidine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Quinidine is mainly metabolised by CYP3A4 and to a lesser extent by CYP2C9 and CYP2E1. Quinidine is also a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of orally administered quinidine may increase due to inhibition of CYP3A4 and P-gp. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Similar effects may occur with quinidine. Monitoring for quinidine toxicity is recommended. Furthermore, quinidine is also an inhibitor of CYP2D6 (strong), CYP3A4 (weak) and P-gp (moderate). Concentrations of lapatinib may increase due to inhibition of CYP3A4. The clinical relevance of this interaction is unknown. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. Lapatinib and quinidine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
325,Lapatinib,Rabeprazole,"
Potential Weak Interaction
","
Moderate
","Coadministration has not been studied. Rabeprazole is mainly metabolised via non-enzymatic reduction and to a lesser extent by CYP2C19 and CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of rabeprazole may increase. Since CYP3A4 is a minor pathway, no clinically relevant effect on rabeprazole exposure is expected. However, the solubility of lapatinib is pH-dependent. Pre-treatment with a proton pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 26%. A similar effect may occur with rabeprazole. A decrease in exposure may lead to a decrease in lapatinib efficacy. If coadministration is unavoidable, monitor lapatinib efficacy and plasma concentrations of lapatinib, if available.",See Summary
326,Lapatinib,Ramipril,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ramipril is hydrolysed to the active metabolite ramiprilat, and is metabolised to the diketopiperazine ester, diketopiperazine acid and the glucuronides of ramipril and ramiprilat. Lapatinib is not expected to interact with these metabolic pathways. ",See Summary
327,Lapatinib,Ranitidine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ranitidine is excreted via OAT1/OAT3. Lapatinib does not inhibit or induce OAT1/OAT3. However, the solubility of lapatinib is pH-dependent. Pre-treatment with a proton pump inhibitor (esomeprazole) decreased lapatinib exposure by an average of 26%. A similar effect may occur with ranitidine. A decrease in exposure may lead to a decrease in lapatinib efficacy. If coadministration is unavoidable, monitor lapatinib efficacy and plasma concentrations of lapatinib, if available.",See Summary
328,Lapatinib,Ranolazine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Ranolazine is primarily metabolised by CYP3A4 and to a lesser extent by CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with ranolazine. Ranolazine is also a substrate of P-gp. Lapatinib is an inhibitor of P-gp. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with ranolazine. If coadministration appears necessary, monitoring of blood pressure is recommended. Furthermore, ranolazine is a weak inhibitor of P-gp, CYP3A4 and CYP2D6. Concentrations of lapatinib may increase due to inhibition of CYP3A4 and P-gp. Caution should be exercised. Monitor for lapatinib toxicity. If available measure lapatinib plasma concentrations. Additionally, lapatinib and ranolazine may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
329,Lapatinib,Reboxetine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Reboxetine is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered reboxetine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with reboxetine. Care should be taken when orally administered reboxetine is coadministered with lapatinib. Monitoring for reboxetine toxicity is recommended. Furthermore, in vitro data indicate reboxetine to be a weak inhibitor of CYP3A4 but in vivo data showed no inhibitory effect on CYP3A4. Therefore, no effect on lapatinib exposure is expected. ",See Summary
330,Lapatinib,Repaglinide,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Repaglinide is metabolised by CYP2C8 and CYP3A4, with clinical data indicating it is a substrate of OATP1B1. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Furthermore, lapatinib is an in vitro inhibitor of CYP2C8 and OATP1B1 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring of blood glucose levels is recommended and adjust repaglinide dose accordingly.",See Summary
331,Lapatinib,Retinol (Vitamin A),"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vitamin A esters are hydrolysed by pancreatic enzymes to retinol, which is then absorbed and re-esterified. Some retinol is stored in the liver, but retinol not stored in the liver undergoes glucuronide conjugation and subsequent oxidation to retinal and retinoic acid. Lapatinib does not interact with this metabolic pathway. ",See Summary
332,Lapatinib,Riboflavin (Vitamin B2),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.,See Summary
333,Lapatinib,Rifabutin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Rifabutin is metabolised by CYP3A and via deacetylation. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered rifabutin may increase. Since rifabutin is a strong CYP3A4 inducer itself, a clinically relevant effect on rifabutin exposure is not expected. However, rifabutin is a strong CYP3A4 and P-gp inducer, and may decrease concentrations of lapatinib. In healthy volunteers, coadministration of lapatinib and carbamazepine, a strong CYP3A4 inducer, decreased systemic exposure of lapatinib by approximately 72%. A similar effect may occur after coadministration with rifabutin. Coadministration should be avoided. Selection of an alternative concomitant medication with no or minimal enzyme induction potential is recommended. If lapatinib must be concomitantly used with a strong CYP3A4 inducer, based on pharmacokinetic studies, the dose of lapatinib should be titrated up by a factor of 3-4, based on tolerability. If rifabutin is discontinued, the lapatinib dose should be reduced to the indicated dose. Monitor lapatinib plasma concentrations, if available.",See Summary
334,Lapatinib,Rifampicin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Rifampicin is metabolised via deacetylation. Lapatinib does not interact with this metabolic pathway. However, rifampicin is a strong CYP3A4 and P-gp inducer and may decrease concentrations of lapatinib. In healthy volunteers, coadministration of lapatinib and carbamazepine, a strong CYP3A4 inducer, decreased systemic exposure of lapatinib by approximately 72%. A similar effect may occur after coadministration with rifampicin. Coadministration should be avoided. Selection of an alternative concomitant medication with no or minimal enzyme induction potential is recommended. If lapatinib must be concomitantly used with a strong CYP3A4 inducer, based on pharmacokinetic studies, the dose of lapatinib should be titrated up by a factor of 3-4, based on tolerability. If rifampicin is discontinued, the lapatinib dose should be reduced to the indicated dose. Monitor lapatinib plasma concentrations, if available.",See Summary
335,Lapatinib,Rifapentine,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Rifapentine is metabolised via deacetylation. Lapatinib does not interact with this metabolic pathway. However, rifapentine is a strong CYP3A4, CYP2C8 and P-gp inducer, and may decrease concentrations of lapatinib. In healthy volunteers, coadministration of lapatinib and carbamazepine, a strong CYP3A4 inducer, decreased systemic exposure of lapatinib by approximately 72%. A similar effect may occur after coadministration with rifapentine. Coadministration should be avoided. Selection of an alternative concomitant medication with no or minimal enzyme induction potential is recommended. If lapatinib must be concomitantly used with a strong CYP3A4 inducer, based on pharmacokinetic studies, the dose of lapatinib should be titrated up by a factor of 3-4, based on tolerability. If rifapentine is discontinued, the lapatinib dose should be reduced to the indicated dose. Monitor lapatinib plasma concentrations, if available.",See Summary
336,Lapatinib,Rifaximin,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rifaximin is mainly excreted in faeces, almost entirely as unchanged drug. Lapatinib does not interact with this elimination pathway. ",See Summary
337,Lapatinib,Risperidone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Risperidone is metabolised by CYP2D6 and to a lesser extent by CYP3A4. Risperidone is also a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp and may increase concentrations of risperidone. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with risperidone. Therefore, caution should be exercised and dose reduction of risperidone should be considered. Monitor for risperidone toxicity.",See Summary
338,Lapatinib,Rivaroxaban,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Rivaroxaban is partly metabolised in the liver (by CYP3A4, CYP2J2 and hydrolytic enzymes) and partly eliminated unchanged in urine (by P-gp and BCRP). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of rivaroxaban may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with rivaroxaban. Furthermore, coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with rivaroxaban. Caution should be exercised and a dose reduction of rivaroxaban should be considered. Monitoring for rivaroxaban toxicity and anti-Xa activity, if available, is recommended.",See Summary
339,Lapatinib,Rosiglitazone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Rosiglitazone is metabolised mainly by CYP2C8 and to a lesser extent by CYP2C9. Lapatinib is an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring of blood glucose levels is recommended and adjust rosiglitazone dose accordingly.",See Summary
340,Lapatinib,Rosuvastatin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rosuvastatin is largely excreted unchanged via the faeces via OATP1B1 and is a substrate of BCRP. Lapatinib is an in vitro inhibitor of OATP1B1 and BCRP at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for rosuvastatin toxicity may be required.",See Summary
341,Lapatinib,Salbutamol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salbutamol is metabolised to the inactive salbutamol-4’-O-sulphate. Lapatinib does not interact with this metabolic pathway.,See Summary
342,Lapatinib,Salmeterol,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Salmeterol is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. However, since salmeterol is not orally administered, no clinically relevant interaction is expected.",See Summary
343,Lapatinib,Saxagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Saxagliptin is mainly metabolised by CYP3A4 and is a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of saxagliptin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Similar effects may occur with saxagliptin. Monitoring of blood glucose levels is recommended and adjust saxagliptin dose accordingly.",See Summary
344,Lapatinib,Senna,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Senna glycosides are hydrolysed by colonic bacteria in the intestinal tract and the active anthraquinones liberated into the colon. Excretion occurs in the urine and the faeces, but also in other secretions. No clinically significant drug interactions are known. ",See Summary
345,Lapatinib,Sertindole,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but is contraindicated. Sertindole is metabolised by CYP2D6 and CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered sertindole may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with sertindole. Furthermore, the product labels for sertindole contraindicate its use in the presence of other drugs that prolong the QT interval, such as lapatinib.",See Summary
346,Lapatinib,Sertraline,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sertraline is mainly metabolised by CYP2B6 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered sertraline may increase. However, since CYP3A4 is a minor pathway, no clinically relevant effect on sertraline exposure is expected.",See Summary
347,Lapatinib,Sildenafil (Pulmonary Arterial Hypertension),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Sildenafil is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C9. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of sildenafil may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with sildenafil. Care should be taken when orally administered sildenafil is coadministered with lapatinib. Monitoring for sildenafil toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant interaction is expected.",See Summary
348,Lapatinib,Simvastatin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied but care should be taken. Simvastatin is metabolised by CYP3A4 and the metabolite is a substrate of OATP1B1. Simvastatin is also a substrate of BCRP. Lapatinib is an in vitro inhibitor of BCRP and OATP1B1 at clinically relevant concentrations. Lapatinib is also a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an in vitro inhibtior of OATP1B1. Concentrations of simvastatin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with simvastatin. If coadministration is unavoidable, monitor for simvastatin toxicity.",See Summary
349,Lapatinib,Sirolimus,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Sirolimus is metabolised by CYP3A4 and is a substrate of P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered sirolimus may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with sirolimus. Furthermore, lapatinib inhibits P-gp. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with sirolimus. Caution should be exercised and dose reduction of sirolimus should be considered. Monitor for sirolimus toxicity and, if available, plasma concentrations.",See Summary
350,Lapatinib,Sitagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Sitagliptin is primarily eliminated in urine as unchanged drug (active secretion by OAT3, OATP4C1, and P-gp) and metabolism by CYP3A4 represents a minor elimination pathway. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of sitagliptin may increase. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with sitagliptin. Monitoring of blood glucose levels is recommended and adjust sitagliptin dose accordingly.",See Summary
351,Lapatinib,Sodium nitroprusside,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Sodium nitroprusside is rapidly metabolised, likely by interaction with sulfhydryl groups in the erythrocytes and tissues. Cyanogen (cyanide radical) is produced which is converted to thiocyanate in the liver by the enzyme thiosulfate sulfurtransferase. There is little potential for sodium nitroprusside to affect the disposition of lapatinib, or to be affected if co-administered with lapatinib. ",See Summary
352,Lapatinib,Sotalol,"
Potential Interaction
","
Low
","Coadministration has not been studied and should be approached with caution. Sotalol is excreted unchanged via renal elimination. Lapatinib does not interfere with this elimination pathway. However, coadministration is not recommended due to the potential of life threatening arrhythmias such as torsade de pointes and sudden death. The product labels for sotalol advise extreme caution if given with other drugs that prolong the QT interval, such as lapatinib. ",See Summary
353,Lapatinib,Spectinomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spectinomycin is predominantly eliminated unchanged in the kidneys via glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
354,Lapatinib,Spironolactone,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Spironolactone is partly metabolised by the flavin containing monooxygenases. Lapatinib does not interfere with this metabolic pathway.,See Summary
355,Lapatinib,Stanozolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Stanozolol undergoes hepatic metabolism. Lapatinib is unlikely to interact with this pathway.,See Summary
356,Lapatinib,St John's Wort,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but should be avoided. St John’s Wort is an inducer of CYP3A4 and P-gp, and may cause significant and unpredictable decreases in the plasma concentrations of lapatinib.",See Summary
357,Lapatinib,Streptokinase,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Like other proteins, streptokinase is metabolised proteolytically in the liver and eliminated via the kidneys. Streptokinase is unlikely to affect the disposition of lapatinib, or to be affected if coadministered with lapatinib.",See Summary
358,Lapatinib,Streptomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Streptomycin is eliminated by glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
359,Lapatinib,Sulfadiazine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. In vitro studies suggest a role of CYP2C9 in sulfadiazine metabolism. Lapatinib does not inhibit or induce CYP2C9.,See Summary
360,Lapatinib,Sulpiride,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Sulpiride is mainly excreted in the urine and faeces as unchanged drug. Lapatinib is unlikely to interfere with this elimination pathway. However, lapatinib and sulpiride may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
361,Lapatinib,Tacrolimus,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Tacrolimus is metabolised mainly by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered tacrolimus may increase. If coadministration is unavoidable, care should be taken when orally administered tacrolimus is coadministered with lapatinib. Monitoring for tacrolimus toxicity is recommended. Monitor tacrolimus concentrations, if available. Furthermore, tacrolimus inhibits CYP3A4 and OATP1B1 in vitro but produced modest inhibition of CYP3A4 and OATP1B1 in the range of clinical concentrations. Tacrolimus could potentially increase lapatinib concentrations due to CYP3A4 inhibition although to a modest extent. No a priori dosage adjustment is recommended. ",See Summary
362,Lapatinib,Tadalafil (Pulmonary Arterial Hypertension),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Tadalafil is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of tadalafil may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with tadalafil. Care should be taken when orally administered tadalafil is coadministered with lapatinib. Monitoring for tadalafil toxicity is recommended.",See Summary
363,Lapatinib,Tamsulosin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Tamsulosin is metabolised mainly by CYP3A4 and to a lesser extent by CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered tamsulosin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with tamsulosin. Care should be taken when orally administered tamsulosin is coadministered with lapatinib. Monitoring for tamsulosin toxicity is recommended. ",See Summary
364,Lapatinib,Tazobactam,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tazobactam is excreted as unchanged drug (approximately 80%) and inactive metabolite (approximately 20%) in the urine. Lapatinib does not interfere with this elimination pathway.,See Summary
365,Lapatinib,Telithromycin,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Telithromycin is metabolised by CYP3A4 (50%) with the remaining 50% metabolised via non-CYP mediated pathways. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered telithromycin may increase. Care should be taken when orally administered telithromycin is coadministered with lapatinib. Monitoring for telithromycin toxicity is recommended. Furthermore, telithromycin is a strong inhibitor of CYP3A4 and may increase concentrations of lapatinib. In healthy volunteers, coadministration of lapatinib and ketoconazole, a strong CYP3A4 inhibitor, increased lapatinib exposure by approximately 3.6-fold. A similar effect may occur with telithromycin. Coadministration should be avoided. If coadministration is unavoidable, a dose reduction of 50-66% for lapatinib is recommended, based on pharmacokinetic studies. Monitor closely for lapatinib toxicity, including ECG. Monitor lapatinib plasma concentrations, if available.",See Summary
366,Lapatinib,Telmisartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Telmisartan is mainly glucuronidated by UGT1A3. Lapatinib does not inhibit or induce UGT1A3. ,See Summary
367,Lapatinib,Temazepam,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Temazepam is mainly glucuronidated. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for temazepam toxicity may be required.",See Summary
368,Lapatinib,Terbinafine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Terbinafine is metabolised by CYPs 1A2, 2C9, 3A4 and to a lesser extent by CYPs 2C8 and 2C19. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. Concentrations of orally administered terbinafine may increase. The clinical relevance of this interaction is unknown. Caution should be exercised and dose reduction of terbinafine should be considered. Monitor for terbinafine toxicity. Furthermore, terbinafine is a moderate-strong inhibitor of CYP2D6. Lapatinib is not metabolised by CYP2D6.",See Summary
369,Lapatinib,Testosterone,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Testosterone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered testosterone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with testosterone. Care should be taken when orally administered testosterone is coadministered with lapatinib. Monitoring for testosterone toxicity is recommended. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
370,Lapatinib,Tetracycline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tetracycline is eliminated unchanged primarily by glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
371,Lapatinib,Theophylline,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Theophylline is mainly metabolised by CYP1A2. Lapatinib does not inhibit or induce CYP1A2.,See Summary
372,Lapatinib,Thiamine (Vitamin B1),"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
373,Lapatinib,Thioridazine,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but is contraindicated. Based on metabolism and clearance a pharmacokinetic interaction is unlikely. Thioridazine is metabolised by CYP2D6 and to a lesser extent by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway, no clinically relevant effect on thioridazine exposure is expected. However, the product labels for thioridazine contraindicate its use in the presence of other drugs that prolong the QT interval, such as lapatinib.",See Summary
374,Lapatinib,Tiapride,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Tiapride is excreted largely unchanged in urine. Lapatinib is unlikely to interfere with this elimination pathway. However, lapatinib and tiapride may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
375,Lapatinib,Ticagrelor,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Ticagrelor is a substrate of CYP3A4 and P-gp. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Lapatinib is also an inhibitor of P-gp. Concentrations of ticagrelor may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased ticagrelor AUC by 45%. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. Similar effects may occur with ticagrelor. Care should be taken when orally administered ticagrelor is coadministered with lapatinib. Monitoring for ticagrelor toxicity is recommended. A thrombocyte aggregation function test is also recommended. Furthermore, ticagrelor is a weak inhibitor of CYP3A4 and may increase concentrations of lapatinib. The clinical relevance of this interaction is unknown. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered.",See Summary
376,Lapatinib,Timolol,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Timolol is predominantly metabolised in the liver by CYP2D6. Lapatinib does not inhibit or induce CYP2D6.,See Summary
377,Lapatinib,Tinzaparin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinzaparin is renally excreted as unchanged or almost unchanged drug. Lapatinib does not interfere with this elimination pathway.,See Summary
378,Lapatinib,Tolbutamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tolbutamide is mainly metabolised by CYP2C9 and to a lesser extent by CYPs 2C8 and 2C19. Lapatinib is an in vitro inhibitor of CYP2C8 at clinically relevant concentrations. Since CYP2C8 is a minor pathway, a clinically relevant interaction is unlikely.",See Summary
379,Lapatinib,Tolterodine,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Tolterodine is primarily metabolised by CYP2D6 with CYP3A4 playing a minor role. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered tolterodine may increase. However, since CYP3A4 is a minor pathway, no clinically relevant effect on tolterodine exposure is expected. Furthermore, multiple oral therapeutic (4 mg) and supratherapeutic (8 mg) doses of tolterodine have been shown to prolong the QTc interval. As lapatinib and tolterodine may both cause QTc interval prolongation, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
380,Lapatinib,Torasemide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Torasemide is metabolised mainly by CYP2C9. Lapatinib does not inhibit or induce CYP2C9. Furthermore, OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Lapatinib is unlikely to interfere with this elimination pathway.",See Summary
381,Lapatinib,Tramadol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Tramadol is metabolised by CYPs 3A4, 2B6, and 2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered tramadol may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with tramadol. Care should be taken when orally administered tramadol is coadministered with lapatinib. Monitoring for tramadol toxicity is recommended. For administration routes other than oral (e.g. i.v. drugs), no clinically relevant interaction is expected.",See Summary
382,Lapatinib,Trandolapril,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trandolapril is hydrolysed to trandolaprilat. Lapatinib does not interact with this metabolic pathway. ,See Summary
383,Lapatinib,Tranexamic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranexamic acid is mainly cleared by glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
384,Lapatinib,Tranylcypromine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tranylcypromine is hydroxylated and acetylated. Lapatinib does not interact with this metabolic pathway. ,See Summary
385,Lapatinib,Trazodone,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but is not recommended. Trazodone is primarily metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered trazodone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with trazodone. Care should be taken when orally administered trazodone is coadministered with lapatinib. Monitoring for trazodone toxicity is recommended. Furthermore, lapatinib and trazodone may cause QTc interval prolongation. Therefore, coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
386,Lapatinib,Triamcinolone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Triamcinolone is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered triamcinolone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45% A similar effect may occur with triamcinolone. Care should be taken when orally administered triamcinolone is coadministered with lapatinib. Monitoring for triamcinolone toxicity is recommended.",See Summary
387,Lapatinib,Triazolam,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Triazolam is metabolised by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered triazolam may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with triazolam. Care should be taken when orally administered triazolam is coadministered with lapatinib. Monitoring for triazolam toxicity is recommended.",See Summary
388,Lapatinib,Trimethoprim/Sulfamethoxazole,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimethoprim is primarily eliminated by the kidneys through glomerular filtration and tubular secretion. To a lesser extent (approximately 30%) trimethoprim is metabolised by CYP-enzymes (in vitro data suggest CYPs 3A4, 1A2 and 2C9). Lapatinib is weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway, a clinically relevant interaction is unlikely. Trimethoprim is a weak CYP2C8 inhibitor and in vitro data also suggest that trimethoprim is an inhibitor of OCT2 and MATE1. Concentrations of lapatinib may increase due to CYP2C8 inhibition, but since CYP2C8 is a minor pathway, a clinically relevant interaction is not expected. Sulfamethoxazole is metabolised via and is a weak inhibitor of CYP2C9. Lapatinib does not interact with CYP2C9.",See Summary
389,Lapatinib,Trimipramine,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimipramine is metabolised mainly by CYP2D6. Lapatinib does not inhibit or induce CYP2D6.,See Summary
390,Lapatinib,Tropisetron,"
Potential Interaction
","
Very Low
","Coadministration has not been studied. Tropisetron is metabolised mainly by CYP2D6 and is a substrate of P-gp. Lapatinib is an inhibitor of P-gp and may increase concentrations of tropisetron. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with tropisetron. Monitoring for toxicity is recommended. Furthermore, lapatinib and tropisetron may cause QTc interval prolongation. Coadministration is not recommended. If coadministration is unavoidable, close ECG monitoring is recommended.",See Summary
391,Lapatinib,Ulipristal,"
Do Not Coadminister
","
Very Low
","Coadministration is contraindicated if lapatinib is used for treatment of hormone-sensitive cancer. If used for hormone insensitive tumours the following information is applicable: Coadministration has not been studied. Ulipristal is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of ulipristal may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with ulipristal. Care should be taken when orally administered ulipristal is coadministered with lapatinib. Monitoring for ulipristal toxicity may be required.",See Summary
392,Lapatinib,Valproic acid (Valproate),"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Valproic acid is primarily metabolised by glucuronidation (50%) and mitochondrial beta-oxidation (30-40%). To a lesser extent (10%) valproic acid is metabolised by CYP2C9 and CYP2C19. Lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. As the clinical relevance of this interaction is unknown, monitoring for valproic toxicity may be required. Valproic acid is also an inhibitor of CYP2C9. Lapatinib is not metabolised by CYP2C9.",See Summary
393,Lapatinib,Valsartan,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Valsartan is eliminated unchanged mostly through biliary excretion. Lapatinib does not interact with this elimination pathway.,See Summary
394,Lapatinib,Vancomycin,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Vancomycin is excreted unchanged via glomerular filtration. Lapatinib does not interfere with this elimination pathway.,See Summary
395,Lapatinib,Venlafaxine,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Venlafaxine is mainly metabolised by CYP2D6 and to a lesser extent by CYPs 3A4, 2C19 and 2C9. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered venlafaxine may increase. However, since CYP3A4 is a minor pathway, no clinically relevant effect on venlafaxine exposure is expected.",See Summary
396,Lapatinib,Verapamil,"
Potential Interaction
","
Very Low
","Coadministration has not been studied but should be approached with caution. Verapamil is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 1A2, 2C8 and 2C9. Lapatinib inhibits CYP2C8 in vitro at clinically relevant concentrations, but the clinical relevance of CYP2C8 inhibition is unknown. Lapatinib is also a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of verapamil may increase due to CYP3A4 and CYP2C8 inhibition. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with verapamil. Monitoring of blood pressure is recommended. Furthermore, verapamil is a moderate inhibitor of CYP3A4 and may increase lapatinib concentrations. Coadministration of lapatinib with verapamil should be approached with caution. Selection of an alternate concomitant medicinal product, with no or minimal potential to inhibit CYP3A4 should be considered. If coadministration is unavoidable, monitor closely for lapatinib toxicity. Monitor lapatinib plasma concentrations, if available.",See Summary
397,Lapatinib,Vildagliptin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Vildagliptin is inactivated via non-CYP mediated hydrolysis. Vildagliptin is also a substrate of P-gp. Lapatinib is an inhibitor of P-gp and may increase concentrations of vildagliptin. Coadministration of lapatinib and digoxin, a P-gp substrate, increased digoxin AUC by 80%. A similar effect may occur after coadministration with vildagliptin. Monitoring of blood glucose levels is recommended and adjust vildagliptin dose accordingly.",See Summary
398,Lapatinib,Vitamin E,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. ,See Summary
399,Lapatinib,Voriconazole,"
Do Not Coadminister
","
Very Low
","Coadministration has not been studied but should be avoided. Voriconazole is metabolised by CYP2C19 (major) and to a lesser extent by CYP3A4 and CYP2C9. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Since CYP3A4 is a minor pathway, no clinically relevant effect on voriconazole exposure is expected. Furthermore, voriconazole is a strong inhibitor of CYP3A4 and a weak inhibitor of CYPs 2C9, 2C19 and 2B6. Concentrations of lapatinib may increase due inhibition of CYP3A4. In healthy volunteers, coadministration of lapatinib and ketoconazole, a strong CYP3A4 inhibitor, increased lapatinib exposure by approximately 3.6-fold. A similar effect may occur with voriconazole. Coadministration should be avoided. If coadministration is unavoidable, a dose reduction of 50-65% for lapatinib is recommended, based on pharmacokinetic studies. Monitor closely for lapatinib toxicity, including ECG. Monitor lapatinib plasma concentrations, if available.",See Summary
400,Lapatinib,Warfarin,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Warfarin is a mixture of enantiomers which are metabolised by different cytochromes. R-warfarin is primarily metabolised by CYP1A2 and CYP3A4. S-warfarin (more potent) is metabolised by CYP2C9. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered warfarin may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45% increase. A similar effect may occur with warfarin. Care should be taken when orally administered warfarin is coadministered with lapatinib. Monitoring for warfarin toxicity and INR/PT is recommended when coadministered with lapatinib.",See Summary
401,Lapatinib,Xipamide,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Approximately 90% of xipamide is excreted in the urine, mainly as unchanged drug (~50%) and glucuronides (30%). OAT1/3 are the major transporters of loop and thiazide diuretics. Secretion of these diuretics into the urinary tract by transporters in the proximal tubular cells is necessary for the diuretic effect in later tubule segments. Lapatinib is unlikely to interfere with this elimination pathway.",See Summary
402,Lapatinib,Zaleplon,"
No Interaction Expected
","
Very Low
","Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zaleplon is mainly metabolised by aldehyde oxidase and to a lesser extent by CYP3A4. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered zaleplon may increase, but since CYP3A4 is a minor pathway, no clinically relevant effect on zaleplon exposure is expected.",See Summary
403,Lapatinib,Ziprasidone,"
Do Not Coadminister
","
Low
","Coadministration has not been studied but is contraindicated. Based on metabolism and clearance a pharmacokinetic interaction is unlikely. Approximately two thirds of ziprasidone metabolic clearance is by reduction, with less than one third by CYP enzymes (mainly CYP3A4). Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered ziprasidone may increase, but since CYP3A4 is a minor pathway, no clinically significant effect on ziprasidone exposure is expected. However, the product labels for ziprasidone contraindicate its use in the presence of other drugs that prolong the QT interval, such as lapatinib. ",See Summary
404,Lapatinib,Zoledronic acid,"
No Interaction Expected
","
Very Low
",Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Zoledronic acid is not metabolised but is cleared from the plasma by uptake into bone and elimination via renal excretion. Lapatinib does not interfere with this elimination pathway.,See Summary
405,Lapatinib,Zolpidem,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Zolpidem is metabolised mainly by CYP3A4 and to a lesser extent by CYPs 2C9, 2C19, 2D6 and 1A2. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered zolpidem may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with zolpidem. Care should be taken when orally administered zolpidem is coadministered with lapatinib. Monitoring for toxicity is recommended. ",See Summary
406,Lapatinib,Zopiclone,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Zopiclone is metabolised mainly by CYP3A4 and to a lesser extent by CYP2C8. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered zopiclone may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam by 45%. A similar effect may occur with zopiclone. Lapatinib is an in vitro inhibitor of CYP2C8 at clinically relevant concentrations, but the clinical significance of this interaction is unknown. Care should be taken when zopiclone is coadministered with lapatinib. Monitoring for zopiclone toxicity is recommended.",See Summary
407,Lapatinib,Zotepine,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Zotepine is mainly metabolised by CYP3A4 and to a lesser extent by CYP1A2 and CYP2D6. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered zotepine may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with zotepine. Care should be taken when orally administered zotepine is coadministered with lapatinib. Monitoring for zotepine toxicity is recommended. For administration routes other than oral, no clinically relevant interaction is expected.",See Summary
408,Lapatinib,Zuclopenthixol,"
Potential Weak Interaction
","
Very Low
","Coadministration has not been studied. Zuclopenthixol is metabolised by sulphoxidation, N-dealkylation (via CYP2D6 and CYP3A4) and glucuronidation. Lapatinib is a weak inhibitor of intestinal CYP3A4 but is not an inhibitor of hepatic CYP3A4. Concentrations of orally administered zuclopenthixol may increase. Coadministration of lapatinib with orally administered midazolam, a CYP3A4 substrate, increased midazolam AUC by 45%. A similar effect may occur with zuclopenthixol. Furthermore, lapatinib is an in vitro inhibitor of UGT1A1 and UGT2B17 at clinically relevant concentrations. The clinical relevance of this interaction is unknown. Care should be taken when orally administered zuclopenthixol is coadministered with lapatinib. Monitoring for zuclopenthixol toxicity is recommended.",See Summary
